

From A to Z

On Hepatitis C in Thalassemia

Comprehensive Guidelines
for Medical Professionals

Edited by:

Seyed Moayed Alavian M.D.,

Professor of Medicine, Gastroenterologist
and Hepatologist, Director Middle East
Liver Disease Center

— IN THE NAME OF —

— GOD —

From A to Z

On Hepatitis C in Thalassemia

**Comprehensive Guideline for
Medical Practitioners**

Seyed Moayed Alavian M.D,
Professor of Medicine,
Gastroenterologist and Hepatologist,
Director Middle East Liver Disease Center



سرشناسنامه

علویان، سید موید، ۱۳۴۱-

Alavaian, Seyyed Moayed

From A to Z on Hepatitis C in thalassemia
/comprehensive guidelines for medical practitioners
.seyed Moayed Alavian

عنوان و نام پدیدآور

مشخصات نشر

تهران: شرکت تعاونی پزشکان سلامت پژوهان کوثر، ۲۰۱۳م=۱۳۹۱.

مشخصات ظاهری

۷۲ ص: مصور، جدول: نمودار.

شابک

1-1-93484-600-978-00:۲۵۰۰ ریال

وضعیت فهرست نویسی

فیبا

یادداشت

انگلیسی.

یادداشت

نمایه .

آوانویسی عنوان

فرام ...

موضوع

هیپاتیت ث

رده بندی کنگره

۱۳۹۱ ع۸/۲۳هـ/۸۴۸/۸۴۸

رده بندی دیویی

۳۶۲۳/۶۱۶

شماره کتابشناسی ملی

۳۰۵۱۵۰۰

نام کتاب:

From A to Z On Hepatitis C in Thalassemia
Comprehensive Guideline for Medical
Practitioners

ناشر:

انتشارات کوثر

تألیف:

دکتر سید موید علویان

صفحه آرایه:

سمیرا واشقانی

طراحی جلد:

پیام فرامرزیان

نوبت چاپ:

۱

لیتوگرافی و چاپ:

نقش جوهر

شمارگان:

۳۰۰۰

قیمت:

۲۵۰۰۰ ریال

Contents

Chapter 1 	
Virology	7
Chapter 2 	
Epidemiology	12
Chapter 3 	
Natural History	26
Chapter 4 	
Diagnosis and evaluation	34
Chapter 5 	
Treatment	42

Preface

Thalassemia patients have a high prevalence of hepatitis C virus (HCV) infections. Recent improvements in the survival of these patients are a result of more services for the control of iron overload, the provision of safe blood, and better control of complications. Today, liver disease is the main cause of mortality in thalassemia patients throughout the world. Unfortunately, there are inadequate policy in most thalassemia centers for the control of HCV infections. Thalassemia patients with HCV infections pose a real dilemma in the management of this infection, and they must have access to adequate professional counseling from health care workers, in addition, the health system should provide appropriate diagnostic and therapeutic options. Therefore, I considered it imperative to provide a book from A to Z for health professionals regarding the epidemiology, screening, diagnosis and treatment of HCV infection in this high risk group. My hope is for improvements in the control of HCV in thalassemia patients in the world, especially in the Mediterranean region.

Chapter 1

Virology


The virus was discovered and characterized by Choo et al. in 1989 (1) by using molecular biology techniques from a chimpanzee infected with the sera of a patient with chronic non-A, non-B hepatitis. Their data indicated that this clone was derived from the genome of the Non-A, Non-B Hepatitis (NANBH) agent and was similar with the agents belonging to the Togaviridae or Flaviviridae viral families (1). Therefore, significant advances in molecular biology have allowed the scientists to explore the details of the virus and to develop a wide variety of antigens and synthetic peptides that have been successfully deployed in immunoassays to detect Hepatitis C virus (HCV) infection.

Hepatitis C virus is an enveloped positive-sense single-stranded RNA virus and the only member of the genus Hepacivirus within the Flaviviridae family. The genome contains a single-stranded RNA, large open reading frame (ORF) with a size 9.4 kb in length and a highly conserved untranslated region (UTR) at the 5' and 3' ends (2) (Figure 1.1). The HCV genome encodes for a viral polyprotein of approximately 3010 amino acids, which

is cleaved after translation to yield 10 viral proteins (3).

The 5' end of its genome consists of an untranslated region containing an internal ribosome entry site and three structural genes, the core region, C, which codes for the nucleocapsid, and the envelope regions, E1 and E2, which code for envelope glycoproteins. The 5' untranslated region and core gene are highly conserved among genotypes, but the envelope proteins are coded by the hypervariable region, which varies from isolate to isolate and may allow the virus to evade the immunological response of the host. Genotype-specific sequence differences exist in the 5' UTR, while the secondary and tertiary structures are essentially preserved. The 5' UTR is required for replication of the negative strand. A liver specific micro-RNA, miRNA-122, with binding sites in the 5' UTR, has been shown to facilitate HCV replication (4).

Figure 1.1 Hepatitis C genome



The 3' end of the genome also includes an untranslated region and contains the genes for six non-structural (NS) proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B. The NS2 protein is a cysteine protease that cleaves the NS2/3 junction and the NS3-4A serine proteases cleave all the downstream proteins from the glycoprotein. Important NS proteins involved in viral replication include the NS3 helicase, NS3-NS4A serine protease, and the NS5B RNA-dependent RNA polymerase. The structural proteins are cleaved from the polyprotein by the viral proteases NS2 and NS3. There is evidence for long-range RNA/RNA interactions between the 5' and 3' UTRs, as well as between the 5' UTR and RNA sequences at the C-terminal of NS5B. These interactions play an essential role in the replication process. Replication of HCV does not need the DNA intermediate and it does not integrate into the host genome. Particles of HCV circulate in a relatively low titer, but

their replication has a very high daily rate, with a half-life of 2.7 hours.

There are at least six genotypes of HCV, and more than 50 subtypes within these genotypes, as well as diverse populations of quasispecies within each infected individual, that have been identified by nucleotide sequencing (5). The source of this variation, like that of other RNA viruses, is the high mutation rate of its error prone RNA polymerase during the HCV replicative process. Shortly after its discovery in 1989, it became clear that HCV had a substantial nucleotide sequence diversity, with only 66–80% overall sequence similarity among strains belonging to different genotypes or subtypes (6). The HCV isolates show four levels of genomic variations: types, subtypes, isolates, and quasispecies. The overall sequence similarities over complete genomic sequences are of at least 91% within quasispecies, approximately 79% (77–80%) between subtypes, and about 68% (66–69%) between different types. This quasispecies is composed of a group of heterogeneous RNA sequences centered on a dominant nucleotide sequence that changes, throughout the course of the infection, under the selective pressure of the host immune system. More than one genotype can be found in the circulation of some HCV-infected patients, particularly in individuals who have received multiple transfusions and intravenous drug users. These are referred to as mixed-genotype infections (7-10).

The HCV genotype has been shown to present unique patterns of geographical distribution and to be a major research instrument in HCV epidemiological studies. In recent years however, a shift in the prevalence of predominant HCV genotypes has been observed in a number of European countries (11-16), in correlation with variations in the modes of HCV acquisition. Different HCV isolates worldwide show substantial nucleotide sequence variability throughout the viral genome. The polymerase chain reaction (PCR) analysis with type-specific primers for identification of the HCV genomic typing enables the separation into six major genotypes (1 to 6) and a series of subtypes (e.g. a, b, c) (17-20). These viral types and subtypes differ in their geographical distribution and antigenicity. Types 1, 2 and 3 are distributed almost worldwide (21-27). Types 4, 5 and 6 have been found in distinct geographical areas (17, 25, 26, 28). Interestingly, not only do the HCV genotypes seem to differ in nucleotide sequence and geographical distribution, but there is also evidence of biological differences between the three HCV genotypes. Patients with HCV subtype 1b have a poorer response

to interferon-alpha treatment. The transmission route may also affect the distribution of HCV genotypes.

Conclusion remarks

- The HCV particles circulate in a relatively low titer but their replication has a very high daily rate, with a half-life of 2.7 hours. The HCV genome encodes for a viral polyprotein of approximately 3010 amino acids, which is cleaved after translation to yield 10 viral proteins;
- The replication of HCV does not need the DNA intermediate and it does not integrate into the host genome;
- There are at least six genotypes of HCV, and more than 50 subtypes within these genotypes, with different geographical distribution.

References

1. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science*. 1989;244(4902):359-62.
2. Joyce MA, Tyrrell DL. The cell biology of hepatitis C virus. *Microbes Infect*. 2010;12(4):263-71. Epub 2010/01/19.
3. Halfon P, Ouzan D, Khiri H, Feryn JM. Serotyping and genotyping of hepatitis C virus (HCV) strains in chronic HCV infection. *Commission Hepatologie du CREGG. Club de Reflexion des Cabinets de Groupes en GastroEnterologie. J Med Virol*. 1997;52(4):391-5.
4. Jopling CL, Norman KL, Sarnow P. Positive and negative modulation of viral and cellular mRNAs by liver-specific microRNA miR-122. *Cold Spring Harbor symposia on quantitative biology*. 2006;71:369-76. Epub 2007/03/27.
5. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology*. 2005;42(4):962-73.
6. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. *Hepatology*. 1994;19(5):1321-4. Epub 1994/05/01.
7. Ahmadi Pour MH, Alavian SM, Amini S, Azadmanesh K. Hepatitis C Virus Genotypes. *Hepat Mon*. 2005;5(3):77-82.
8. Ahmadi Pour MH, Keivani H, Sabahi F, Alavian SM. Determination of HCV genotypes, in Iran by PCR-RFLP. *Iran J Public Health*. 2006;35(4):54-61.

9. Bukh J, Purcell RH, Miller RH. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. *Proc Natl Acad Sci USA*. 1993;90:8234-38.
10. Tuveri R, Rothschild C, Pol S, Reijasse D, Persico T, Gazengel C, et al. Hepatitis C virus genotypes in French haemophiliacs: kinetics and reappraisal of mixed infections. *J Med Virol*. 1997;51(1):36-41. Epub 1997/01/01.
11. Chlabicz S, Flisiak R, Kowalczyk O, Grzeszczuk A, Pytel-Krolczuk B, Prokopowicz D, et al. Changing HCV genotypes distribution in Poland—relation to source and time of infection. *J Clin Virol*. 2008;42(2):156-9. Epub 2008/03/21.
12. Ramos B, Nunez M, Toro C, Sheldon J, Garcia-Samaniego J, Rios P, et al. Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: implications for HCV therapy in HCV/HIV-coinfected patients. *J Infect*. 2007;54(2):173-9.
13. Dal Molin G, Ansaldi F, Biagi C, D'Agaro P, Comar M, Croce L, et al. Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. *J Med Virol*. 2002;68(3):352-6.
14. Ross RS, Viazov S, Renzing-Kohler K, Roggendorf M. Changes in the epidemiology of hepatitis C infection in Germany: shift in the predominance of hepatitis C subtypes. *J Med Virol*. 2000;60(2):122-5.
15. Bourliere M, Barberin JM, Rotily M, Guagliardo V, Portal I, Lecomte L, et al. Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users. *J Viral Hepat*. 2002;9(1):62-70.
16. Seme K, Vrhovac M, Mocilnik T, Maticic M, Lesnicar G, Baklan Z, et al. Hepatitis C virus genotypes in 1,504 patients in Slovenia, 1993-2007. *J Med Virol*. 2009;81(4):634-9. Epub 2009/02/25.
17. Simmonds P HE, Cha TA, Chan SW, McOmish F, Irvine B, et al. Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. *J Gen Virol*. 1993;74:2391-99.
18. Simmonds P AA, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. *Hepatology*. 1994;19:1321-24.
19. Stuyver L vAW, Wyseur A, Hernandez F, Delaporte E, Maertens G. Classification of hepatitis C viruses based on phylogenetic analysis of the envelope 1 and nonstructural 5B regions and identification of five additional subtypes. *Proc Natl Acad Sci USA*. 1994;91:10134-38.
20. Tokita H OH, Tsuda F, Song P, Nakata S, Chosa T, et al. Hepatitis C virus variants from Vietnam are classifiable into the seventh, eighth, and ninth major genetic groups. *Proc Natl Acad Sci USA*. 1994;91:11022-26.
21. McOmish F YP, Dow BC, Follett EA, Seed C, Keller AJ, et al. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. *J Clin Microbiol*. 1994;32:884-92.
22. Dusheiko G S-WH, Brown D, McOmish F, Yap PL, Sherlock S, et al. Hepatitis C virus genotypes: an investigation of type-specific differences in geographic origin and disease. *Hepatology*. 1994;19:13-8.
23. Takada N TS, Takada A, Date T. HCV genotypes in different countries. *Lancet*. 1992;339:808.
24. Takada N TS, Takada A, Date T. Differences in the hepatitis C virus genotypes in different countries. *J Hepatol*. 1993;17:277-83.
25. Bukh J PR, Miller RH. At least 12 genotypes of hepatitis C virus predicted by sequence analysis of the putative E1 gene of isolates collected worldwide. *Proc Natl Acad Sci USA*. 1993;90:8234-38.
26. Cha TA BE, Irvine B, Kolberg J, Chien D, Kuo G, Urdea MS. At least five related, but distinct, hepatitis C viral genotypes exist. *Proc Natl Acad Sci USA*. 1992;89:7144-48.

27. Chan SW, McOmish F, Holmes EC, Dow B, Peutherer JF, Follett Eea. Analysis of a new hepatitis C virus type and its phylogenetic relationship to existing variants. *J Gen Virol.* 1992;73:1131-41.
28. Simmonds P MF, Yap PL, Chan SW, Lin CK, Dusheiko G, et al. Sequence variability in the 5' non-coding region of hepatitis C virus: identification of a new virus type and restrictions on sequence diversity. *J Gen Virol.* 1993;74:661-68.

Chapter 2

Epidemiology

Introduction

Hepatitis C virus (HCV) has been discovered in 1989 and it is a major cause of liver related morbidity and mortality worldwide, representing a major public health concern, especially during the recent years (1, 2). The average prevalence of HCV infection throughout the world is of 2-3% or 170-200 million persons (3-7). These estimates are often based on volunteer blood donor prevalence rates and may therefore underestimate the true prevalence. Also, the surveys in general populations may have failed to include some high risk groups. Nonetheless, these estimates provide some idea of the worldwide pattern of infection. Overall and age-specific prevalence varies considerably from country to country. The antibody prevalence is low (0.01-0.1%) in the United Kingdom and Scandinavia, slightly higher (0.2-1.8%) in the United States, Western Europe, Australia, and parts of South America and Africa, and intermediate (1-5%) in Eastern Europe, the Mediterranean, Middle East, Indian subcontinent, Brazil, and

parts of Africa and Asia (8). The highest prevalence is in northern Africa, 6% in Zaire (8), 7.9% in Libya (9), and 17-26% in Egypt (8, 10, 11). The prevalence is also high in some areas of Saudi Arabia (12).

The HCV infection is highly prevalent among thalassemia patients, especially in developing countries, and the rate of infection varies markedly from country to country (13). Thalassemia is one of the most common genetic disorders. It is estimated that 300.000 infants with major hemoglobinopathies are born worldwide each year, of whom 60.000-70.000 are beta thalassemia (β -thalassemia) major cases, especially in the Mediterranean area, Middle East, Far East, and East Asia (14-16). Although thalassemia mostly affects developing countries, there is limited knowledge of its accurate frequency and distribution in these regions. Knowing the prevalence of thalassemia and characterizing the clinical features and demography of patients will enable us to properly measure the burden of disease. Thalassemia is characterized by decreased or absent globin chains production. The resultant anemia is caused by the destruction of the erythroblasts in the bone marrow, peripheral hemolysis of the erythrocytes and ineffective erythropoiesis. The life-long need for blood transfusions to maintain a hemoglobin level of at least 9.5 g/dl renders these patients vulnerable to transfusion transmitted viral infections, especially HCV (13). Over the last 20 years, management for thalassemia major has improved to the point where we predict that the patients' life expectancy will approach that of the normal individuals. These outcomes are the result of safer blood transfusions, the availability of three iron chelators, and new imaging techniques that allow specific organ assessment of the degree of iron overload (17). Although regular blood transfusions improve the overall survival of patients with β -thalassemia, they carry a definite risk of infection with blood-borne viruses (18).

Epidemiology

The HCV infection represents a major, worldwide health issue (19). It is estimated that over 170-200 million people are infected and the virus is distributed worldwide with prevalence varying widely between different regions from 0.2-40% (20, 21). While rigorous donor screening, testing pro-

cedures and suitable donor selection programs have dramatically reduced the transmission of HCV via transfusion of blood products, there are still many countries in which standards of blood product management do not adequately ensure the protection of chronically-transfused patients, especially thalassemia patients, from this complication (2, 22, 23).

The prognosis and survival of patients with thalassemia major has dramatically improved in the last two decades due to regular blood transfusions and chelation therapies (24-26) and the main factors that correlated with an increase in the hazard ratio for death were represented by cirrhosis, arrhythmia, previous episode of heart failure, diabetes, hypogonadism, and hypothyroidism (27).

The HCV infection is a widespread disease affecting a large number of thalassemia patients worldwide and is considered a major public health problem in this high risk group. While rigorous donor screening, testing procedures and suitable donor selection programs have dramatically reduced transmission of HCV via transfusion of blood products, pitfalls in the management of blood products in many countries account for the increased rate of HCV infection (2, 13, 23, 28). The prevalence rate in poly-transfused thalassemic patients in different settings increases to up to 60% globally (22, 29-37), but there are tremendous discrepancies between epidemiological studies.

Middle East and EMRO countries status

There is heterogeneity regarding the prevalence of HCV infection in Eastern Mediterranean region. For example, the HCV infection rate ranges from 2-32% in Iran and from 33-93% in Saudi Arabia. Most of these studies also have the drawback of inadequate sample size. In some countries such as Egypt and Jordan, the publication date of available data backs to one or two decades ago and updated data are unavailable.

In a meta-analysis in the Mediterranean and Middle East area on seroepidemiology of HCV infection in thalassemia patients in the EMRO countries, there were 45 relevant published articles that evaluated anti-HCV antibody serostatus in thalassemia patients from EMRO countries (Table 2.1). Unfortunately, no data were available from the following countries:

Table 2.1. Study and patient characteristics from Iran

Ref. No.	Author	Publication year	Design	province	Sample size	ELISA	RIBA	Mean age	Male (%)	Prevalence (95% CI)
(48)	Alavian et al.	2003	Census (C-C)	Qazvin	95	2 nd	Yes	12±7	48%	24% (15-33)
(49)	Mirmomen et al.	2001	C-S	Tehran	410	2 nd	No	22.4±7.8	61%	27% (23-31)
(50)	Alavi et al.	2005	C-S	Tehran	110	2 nd	Yes	11.5±5.2	50%	11% (5-17)
(22)	Mirmomen et al.	2006	C-S	Tehran, Zanjan, Qazvin, Semnan, Ker- man	732	3 rd	Yes	17.9±9.0	56%	19% (17-22)
(51)	Bozorgchi et al.	2008	Census (C-S)	Qazvin	207	3 rd	Yes	14.29±6.5	50%	26% (20-32)
(52)	Kompani et al.	2008	C-S	Khuzestan	195	2 nd	No	14.9±6	50%	21% (15-27)
(53)	Ghafourian et al.	2009	C-S	Khuzestan	206	3 rd	No	16.4±6.42	47%	28% (23-33)
(36)	Tamaddoni et al.	2007	C-S	Mazandaran	113	3 rd	No	15.8±8.93	43%	11% (5-17)
(54)	Ameli et al.	2008	C-S	Mazandaran	65	3 rd	No	19.5±8.9	NR	17% (10-24)
(55)	Shariatzadeh et al.	2000	C-C	Markazi	54	2 nd	Yes	Range (1-36)	NR	9% (1-17)

(35)	Samimi-Rad et al.	2007	C-C	Markazi	98	3 rd	Yes	12.4	51%	5% (1-9)
(56)	Mahdaviyani et al.	2008	Census (C-C)	Markazi	97	3 rd	Yes	13.1±7.3	51%	7% (2-12)
(34)	Ansari et al.	2007	C-S	Fars	806	2 nd	No	15.3±6.82	50%	14% (12-16)
(57)	Akbari et al.	2007	C-C	Fars	200	2 nd	Yes	15.2±6.3	50%	25% (19-31)
(37)	Karimi et al.	2001	C-S	Fars	466	2 nd	Yes	12.3±5.0	52%	16% (13-19)
(58)	Kadivar et al.	2001	C-S	Fars	147	2 nd	Yes	13.6±4.8	55%	27% (20-34)
(59)	Javadzadeh-Shahshahani et al.	2006	Census (C-C)	Yazd	85	2 nd	Yes	12.6±7.56	48%	9% (3-16)
(60)	Hariri et al.	2006	Census (C-S)	Isfahan	616	3 rd	Yes	15.5±8	NR	11% (8-12)
(61)	Faranoush et al.	2006	Census (C-S)	Semnan	63	2 nd	No	11.8±4.7	60%	40% (28-52)
(40)	Zahedi et al.	2003	Census (C-C)	Kerman	100	2 nd	Yes	11.5±5.7	45%	31% (24-38)
(62)	Sanei-Moghaddam et al.	2004	C-S	Sistan and Baluch- istan	364	2 nd	Yes	9.7±5.2	57%	13% (10-16)

ELISA = enzyme linked immunosorbent assay, RIBA = recombinant immunoblot assay
The table is extracted from the article by Alavian SM et al (13) with permission

Table 2.2. The HCV infection rates among polytransfused thalassemia patients from EMRO countries other than Iran.


Country	Author Name	Publication year	Design	Sample size	ELISA	RIBA	age	Male (%)	Prevalence (95% CI)	
Iraq	Al-Kubaisy et al. (41)	2006	C-S	559	3 rd	Yes	2-10	NR	67% (63-71)	
	Akhtar et al. (63)	2004	C-S	256	3 rd	No	NR	NR	34% (28-40)	
Pakistan	Mohammad et al. (64)*	2003	C-S	80	3 rd	No			36% (25-47)	
	Younus et al. (65)	2004	cohort	75	3 rd	No	6.5	64%	42% (31-53)	
	Burki et al. (66)*	2005	C-S	180		No			42% (34-48)	
	Shah et al. (67)	2005	C-S	250	NR	No	5-10 (43%)	72%	57% (51-63)	
	Moatter et al. (68)	1999	C-S	100	2 nd	No	8	57%	34% (25-43)	
	Mukhtar et al. (69)	2005	C-S	250		No			57% (50-62)	
	Hussain et al. (70)*	2008	C-S	180	NR	No	7	NR	42% (34-48)	
	Bahrain	al-Mahroos et al. (71)*	1995	C-C	242		No			32% (26-38)
	Kuwait	Al-Fuzae et al.	1998		129					33% (23.9-40)
	Jordan	Al-Sheyab (39)	2001	C-S	143	NR	No	9	61%	40% (32-48)
Lebanon	Ramia et al. (72)*	2002	C-S	395		No			14% (10-16)	
	Bahakim et al. (73)*	1991	C-C	78		No			33% (23-43)	
Saudi Arabia	al-Fawaz et al. (74)	1996	C-C	28		No		51%	57% (39-75)	
	Al-Hawsawiet al. (75)*	2000		32					91% (80-100)	
Egypt	el Gohary et al. (76)	1995	C-C	45	2 nd	No	NR	NR	76% (64-88)	
	el-Nanawy et al. (77)*	1995	C-C	18		No			44% (21-67)	
Libya	Daw et al. (78)*	2002	C-C	250		No			11% (7-15)	

ELISA = enzyme linked immunosorbent assay, RIBA = recombinant immunoblot assay

The table is extracted from the article by Alavian SM et al (13) with permission

Djibouti, Morocco, Somalia, Sudan, Syria, Emirate, Oman, Qatar, Yemen, West Bank and Afghanistan. There were 21 studies involving 5229 subjects from Iran, eight studies including 1371 subjects from Pakistan, three and two studies with 138 and 42 subjects from Saudi Arabia and Egypt, respectively. Only one study was identified from Bahrain, Iraq, Kuwait, Jordan, Lebanon and Libya (Table 2.1). Mean age of subjects ranged from 9.7–22.4 years of age. Gender distribution ranged from 43–61% male (13). The pooled HCV infection rate was 45% in Pakistan, 63% in Saudi Arabia, 18% in Iran and 69% in Egypt (13). The infection rate among thalassemia patients in countries where only one report was available ranged from 11–14% in Libya and Lebanon to 65% in Iraq (Figure 2.1).

Figure 2.1 Geographical distribution of pooled or individual epidemiology of HCV infection among thalassemia patients in EMRO



The figure is extracted from the article by Alavian SM et al (13) with permission

The thalassemia patients, which represent a high risk group for HCV infection, act as a reservoir of this infection and are one of the main obstacles for HCV infection control in the community. The heterogeneous pattern of the geographical distribution of HCV infection in thalassemia patients indicates that the safety of blood before blood screening varies in different countries and may be related to the different infection prevalencies and to risk factors in blood donors and the general population (22). First transfusion before or after introduction of blood donors screening for anti-HCV an-

tibody was the major determinant of HCV infection in the region. In Kuwait and Jordan, all thalassemia patients transfused were at risk of HCV infection before blood donors screening (1992 in Kuwait and 1995 in Jordan) (38, 39). In Iran, blood donors screening for HCV infection started in 1996. The pooled odds ratio (OR) of HCV infection rate for patients who were transfused before that date was OR: 7.6 (95% CI, 4.7-12.3). This implies an increase in blood safety and more health precautions attention in Iran (22, 35, 40), but data from other EMRO countries are inadequate and inconclusive.

In conclusion, transfusion transmitted diseases are major challenges for the health of patients with hematologic disorders who need to receive regular blood products. Improvement in screening of blood products during 1990s has dramatically decreased the risk of transmission of blood borne diseases via transfusion; however, recent studies have demonstrated that the prevalence of blood borne infections like hepatitis B and C still represent a problem (41-43).

Transmission of HCV

Hepatitis C virus is the second most common cause of chronic hepatitis worldwide and the most common cause of chronic liver disease in areas of the world where hepatitis B virus (HBV) is not endemic. The HCV is transmitted from person to person via blood transfusion, intravenous drug use, and other parenteral exposures. Prior to the development of a screening test for HCV in the early 1990s, the risk of developing non-A-non-B hepatitis from a blood transfusion was 5-10%. Since the development of the anti-HCV assay and the universal screening of all donated blood, the risk of developing HCV following a blood transfusion has declined from about 1:250.000 to 1:500.000. The most common mechanism by which HCV is currently transmitted is represented by the contaminated needles used by intravenous drug users, followed by a break in universal precautions in patients receiving medical care and from the use of reusable and non-sterilized medical equipment in underdeveloped countries. In contrast, the risk of sexual and vertical transmission, although possible, is low, except in individuals with high-risk sexual behaviors and multiple partners and in the setting of HCV-HIV co-infection.

Acute HCV infection is parenterally-acquired and may occur after transfusion of unscreened blood or blood products in thalassemia, as a residual risk. Spontaneous clearance of acute HCV occurs with a high rate within the first 12 weeks of infection and depends on the age the person who acquires the infection (44, 45). The younger the age of infection, the higher is the spontaneous clearance rate of HCV (Unpublished data from the author: about 50% of spontaneous seroconversion of acute HCV in children). The spontaneous clearance rate of HCV in North American thalassemia patients is 33% (46). Because infection with HCV results in chronic infection in a large proportion of infected individuals, it has been suggested that early treatment of acute HCV may limit the development of chronic hepatitis (28).

I would like to sensitize my colleagues about the probability of transmission of HCV infection from patient to patient in thalassemia centers and that the eradication of the virus can prevent nosocomial transmission (13, 35, 47).

Conclusion remarks

- Up to 60% of adult thalassemia patients are infected with HCV infection in the world.
- There is a strong gap in current knowledge about blood safety in Eastern Mediterranean countries. The data were available from 50% of the countries in this region and most of these data had limitations concerning the low sample size and were outdated. The lack of knowledge about blood safety and current serostatus of HCV infection, as the most prevalent transfusion transmitted disease in thalassemia patients, is a major threat to the public health in these countries.
- The heterogeneous pattern of the geographical distribution of HCV infection in thalassemia patients throughout the country indicates that the safety of blood before blood screening differed between provinces and may be related to different prevalence of HCV

infection and risk factors in blood donors and general population.

- Acute HCV infection should be treated as soon as possible in adult thalassemia patients.
- The integration of a surveillance system for periodic checking the HCV infection in all thalassemia patients and reporting the new cases to the ministry of health for follow-up and finding the origin of new infections are strongly recommended.
- Patient to patient transmission of HCV in thalassemia patients should be considered as an important route for horizontal infection and eradication of the virus can prevent this nosocomial transmission.

References

1. Alter MJ. Epidemiology of hepatitis C virus infection. *World J Gastroenterol.* 2007;13(17):2436-41.
2. Alavian SM, Adibi P, Zali MR. Hepatitis C virus in Iran: Epidemiology of an emerging infection. *Arch Iran Med.* 2005;8:84-90.
3. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. *J Viral Hepat.* 1999;6(1):35-47. Epub 2000/06/10.
4. Esteban JI, Esteban L, Viladomiu JC, López-Talavera A, González JM, Hernández M, et al. Hepatitis C virus antibodies among risk groups in Spain. *Lancet.* 1989;ii:294-7.
5. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, et al. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. *J Infect Dis.* 1990;162(4):817-22.
6. Alter MJ, Kouszon-Moran D, Naiman OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med.* 1999;341:556-62.
7. Kiyosawa K, Ichijo T, Tanaka E, Sodeyama T, Kobayashi M. [Epidemiological trend of chronic hepatitis C]. *Nippon Rinsho.* 2001;59(7):1384-8.
8. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. *Semin Liver Dis.* 2000;20(1):1-16.
9. Saleh MG, Pereira LM, Tibbs CJ, Ziu M, al-Fituri MO, Williams R, et al. High prevalence of hepatitis C virus in the normal Libyan population. *Trans R Soc Trop Med Hyg.* 1994;88(3):292-4. Epub 1994/05/01.
10. Abdel-Wahab MF, Zakaria S, Kamel M, Abdel-Khaliq MK, Mabrouk MA, Salama H, et al. High seroprevalence of hepatitis C infection among risk groups in Egypt. *Am J Trop Med Hyg.* 1994;51(5):563-7.
11. Arafat N, El Hoseny M, Rekacewicz C, Bakr I, El-Kafrawy S, El Daly M, et al. Changing pattern of hepatitis C virus spread in rural areas of Egypt. *J Hepatol.* 2005;43(3):418-24.

12. al-Faleh FZ, Ayoola EA, al-Jeffry M, al-Rashed R, al-Mofarreh M, Arif M, et al. Prevalence of antibody to hepatitis C virus among Saudi Arabian children: a community-based study. *Hepatology*. 1991;14(2):215-8.
13. Alavian SM, Tabatabaei SV, Lankarani KB. Epidemiology of HCV Infection among Thalassaemia Patients in eastern Mediterranean Countries: a Quantitative Review of Literature. *Iran Red Cres Med J*. 2010;12(4):365-76.
14. Ahmadnezhad E, Sepehrvand N, Jahani FF, Hatami S, Kargar C, Mirmohammadkhani M, et al. Evaluation and cost analysis of national health policy of thalassaemia screening in west-azerbaijan province of iran. *Int J Prev Med*. 2012;3(10):687-92. Epub 2012/11/01.
15. Angastiniotis M, Modell B, Englezos P, Boulyjenkov V. Prevention and control of haemoglobinopathies. *Bull World Health Organ*. 1995;73(3):375-86. Epub 1995/01/01.
16. Abolghasemi H, Amid A, Zeinali S, Radfar MH, Eshghi P, Rahiminejad MS, et al. Thalassaemia in Iran: epidemiology, prevention, and management. *J Pediatr Hematol Oncol*. 2007;29(4):233-8. Epub 2007/04/07.
17. Berdoukas V, Farmaki K, Carson S, Wood J, Coates T. Treating thalassaemia major-related iron overload: the role of deferiprone. *J Blood Med*. 2012;3:119-29. Epub 2012/11/01.
18. Mansour AK, Aly RM, Abdelrazek SY, Elghannam DM, Abdelaziz SM, Shahine DA, et al. Prevalence of HBV and HCV infection among multi-transfused Egyptian thalassaemic patients. *Hematol Oncol Stem Cell Ther*. 2012;5(1):54-9. Epub 2012/03/27.
19. Alavian SM. Hepatitis C infection in Iran; A review article. *Iran J Clin Infect Dis*. 2009;4(1):47-59.
20. Brown RS, Jr., Gaglio PJ. Scope of worldwide hepatitis C problem. *Liver Transpl*. 2003;9(11):S10-3.
21. Alavian SM. We Need a New National Approach to Control Hepatitis C: It is Becoming too Late. *Hepatitis Monthly*. 2008;8(3):1-3.
22. Mirmomen S, Alavian SM, Hajarizadeh B, Kafaee J, Yektaparast B, Zahedi MJ, et al. Epidemiology of hepatitis B, hepatitis C, and human immunodeficiency virus infections in patients with beta-thalassaemia in Iran: a multicenter study. *Arch Iran Med*. 2006;9:319-23.
23. Wonke B, Hoffbrand AV, Brown D, Dusheiko G. Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. *J Clin Pathol*. 1990;43(8):638-40.
24. Brittenham GM, Griffith PM, Nienhuis AW, McLaren CE, Young NS, Tucker EE, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major. *N Engl J Med*. 1994;331(9):567-73. Epub 1994/09/01.
25. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassaemia. *Blood*. 1997;89(3):739-61. Epub 1997/02/01.
26. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassaemia major treated with deferoxamine. *J Pediatr*. 1991;118(4 Pt 1):540-5. Epub 1991/04/01.
27. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, et al. Improving survival with deferiprone treatment in patients with thalassaemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassaemia and Hemoglobinopathies. *Blood Cells Mol Dis*. 2009;42(3):247-51. Epub 2009/02/24.
28. Alavian SM, Lankarani KB, Sharara A. Treatment of Chronic HCV in Special Populations: Thalassaemia, Hemophilia, and Hemodialysis Patients. *Curr Hepat Rep*. 2012;11(4):256-62.
29. Alavian SM, Kafaee J, Yektaparast B, Hajarizadeh B, Kamali A, Sadri M, et al. [The prev-

- alence of Hepatitis B and C among Thalassemia major patients in Qazvin]. *Kowasr Medical Journal*. 2003;4(7):325-19.
30. Ansar MM, Kooloobandi A. Prevalence of hepatitis C virus infection in thalassemia and haemodialysis patients in north Iran-Rasht. *Journal of Viral Hepatitis*. 2002;9(5):390-2.
 31. Kashef S, Karimi M, Amirghofran Z, Ayatollahi M, Pasalar M, Ghaedian MM, et al. Antiphospholipid antibodies and hepatitis C virus infection in Iranian thalassemia major patients. *Int J Lab Hematol*. 2008;30(1):11-6.
 32. Saberifiroozi M, Yazdankhah S, Karbasi HT. Anti-HCV seropositivity among multiply transfused patients with beta thalassemia major in southern Iran. *Iran J Med Sci*. 1996;21:56-9.
 33. Arababadi MK, Hassanshahi G, Yousefi H, Zarandi ER, Moradi M, Mahmoodi M. No detected hepatitis B virus-DNA in thalassemic patients infected by hepatitis C virus in Kerman province of Iran. *Pak J Biol Sci*. 2008;11(13):1738-41. Epub 2008/09/30.
 34. Ansari H, Kamani H, Arbabi-Sarjo A. Prevalence of hepatitis C and related factors among beta-thalassemia major patients in Southern Iran in 2005-2006. *Journal of Medical Sciences*. 2007;7(6):997-1002.
 35. Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassemia and inherited bleeding disorders in Markazi province, Iran. *Haemophilia*. 2007;13(2):156-63.
 36. Tamaddoni A, Mohammadzadeh I, Ziayi O. Seroprevalence of HCV antibody among patients with beta-thalassemia major in Amirkola Thalassemia Center, Iran. *Iran J Allergy Asthma Immunol*. 2007;6(1):41. Epub 2007/02/17.
 37. Karimi M, Ghavanini AA. Seroprevalence of hepatitis B, hepatitis C and human immunodeficiency virus antibodies among multitransfused thalassaemic children in Shiraz, Iran. *Journal of Paediatrics and Child Health*. 2001;37(6):564-6.
 38. al-Fuzae L, Aboolbacker KC, al-Saleh Q. beta-Thalassaemia major in Kuwait. *J Trop Pediatr*. 1998;44(5):311-2. Epub 1998/11/20.
 39. Al-Sheyyab M, Batieha A, El-Khateeb M. The prevalence of hepatitis B, hepatitis C and human immune deficiency virus markers in multi-transfused patients. *J Trop Pediatr*. 2001;47(4):239-42. Epub 2001/08/29.
 40. Zahedi MJ, Zand V, Tavakoli M, Hajariazdeh B, Alavian SM. [The prevalence of hepatitis B and C among thalassemia major patients in Kerman, Iran, and the role of transfusion in infection acquisition]. *Govaresh*. 2003;8(44):72-8.
 41. Al-Kubaisy WA, Al-Naib KT, Habib M. Seroprevalence of hepatitis C virus specific antibodies among Iraqi children with thalassaemia. *East Mediterr Health J*. 2006;12(1-2):204-10.
 42. Ocak S, Kaya H, Cetin M, Gali E, Ozturk M. Seroprevalence of hepatitis B and hepatitis C in patients with thalassemia and sickle cell anemia in a long-term follow-up. *Arch Med Res*. 2006;37(7):895-8.
 43. Ozyurek E, Ergunay K, Kuskonmaz B, Unal S, Cetin M, Ustacelebi S, et al. Transfusion-transmitted virus prevalence in Turkish patients with thalassemia. *Pediatr Hematol Oncol*. 2006;23(4):347-53.
 44. Hofer H, Watkins-Riedel T, Janata O, Penner E, Holzmann H, Steindl-Munda P, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. *Hepatology*. 2003;37(1):60-4. Epub 2002/12/25.
 45. Pimstone NR, Pimstone D, Saicheur T, Powell J, Yu AS. «Wait-and-see»: an alternative approach to managing acute hepatitis C with high-dose interferon-alpha monother-

- apy. *Ann Intern Med.* 2004;141(6):W91-2.
46. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. *Blood.* 2004;104(1):34-9. Epub 2004/02/28.
 47. Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. *J Viral Hepat.* 2010;17(4):236-44. Epub 2009/07/30.
 48. Alavian S, M,, Kafaei J, Yektaparast B, Hajarizadeh B, Kamali A, Sadri M, et al. The prevalence of Hepatitis B and C among Thalassemia major patients in Qazvin [In Persian]. *Kowasr Medical Journal.* 2003;4(7):325-19.
 49. Mirmomen SH, Ghofrani H, Ebrahimi Daryani N, Niknami H. [Frequency and clinical importance of hepatitis C in thalassemic patients]. *Govaresh.* 2001;6(33-34):120-4.
 50. Alavi S, Arzanian MT, Hatami K, Shirani A. [Frequency of hepatitis C in thalassemic patients and its association with liver enzymes, mofid hospital, Tehran, 2002]. *Research in Medicine, J Shahid Beheshti Univ Med Sci.* 2005;29(3):213-7.
 51. Bozorgi SH, Ramezani H, Vahid T, Kargarfard H, Rezaii M, Ashayeri N, et al. The prevalence and risk factors of hepatitis C virus infection among thalassemic patients of Qazvin (2005)[In Persian]. *J Qazvin Univ Med Sci.* 2008;11(4):54-9.
 52. F. Compani, Rezayi N. Prevalence of HCV Infection and its Association with Impaired Glucose Tolerance and Diabetic Mellitus in Patients with Major Thalassemia *Scientific Journal of Kurdistan University of Medical Sciences.* 2007;12:45-52.
 53. Ghafourian Boroujerdnia M, Assareh Zadegan MA, Zandian KM, Haghirizadeh Rodan M. Prevalence of Hepatitis-C virus (HCV) among Thalassemia Patients in Khuzestan Province, Southwest Iran. *Pak J Med Sci.* 2009;25(1):113-7.
 54. Ameli M, Besharati S, Nemati K, Zamani F. Relationship between elevated liver enzyme with iron overload and viral hepatitis in thalassemia major patients in Northern Iran. *Saudi Med J.* 2008;29(11):1611-5. Epub 2008/11/11.
 55. Shariatzadeh SMA, Nadderi GhA. Study of HBV, HIV and HCV infection in major Thalassemic patients in Central province of Iran [In Persian]. *J Uromia Univ Med Sci.* 2000;1(11):28-0.
 56. Mahdaviani F, Saremi S, Rafiee M. Prevalence of hepatitis B, C and HIV infection in thalassemic and hemophilic patients of Markazi province in 2004 [In Persian]. *Blood, Sci J Iranian Blood Transfus Org Res Cent.* 2008;4(5):313-22.
 57. Akbari A, Imanieh MH, Karimi M, Tabatabaee HR. Hepatitis C virus antibody positive cases in multitransfused thalassemic patients in South of Iran. *Hepat Mon.* 2007;7(2):63-6.
 58. Kadivar MR, Mirahmadizadeh MR, Karimi A, Hemmati A. The prevalence of hepatitis C and Human Immunodeficiency Virus antibodies in thalassemic patients in Shiraz. *Med J Iran Hosp.* 2001;4(1):18-21.
 59. Javadzadeh-Shahshahani H, Attar M, Yavari M, T., Savabieh Sh. Study of the prevalence of Hepatitis B, C and HIV infection in Hemophilia and Thalassemia population of Yazd in 2003 [In Persian]. *Blood, Sci J Iranian Blood Transfus Org Res Cent.* 2006;2(7):315-22.
 60. Hariri MM, Akbari N, Yavari FM, Javadi E, Javer SH. Prevalence of Hepatitis B, C and HIV markers in Thalassemic and Hemophilic patients in Isfahan, 2004 [In Persian]. *Blood, Sci J Iranian Blood Transfus Org Res Cent.* 2006;2(3):201-4.
 61. Faranoush M, Ghorbani R, Amin-Bidokhti ME, Vosoogh P, Malek M, Yazdiha MS. Prevalence of Hepatitis C resulted from blood transfusion in major Thalassemia patients in Semnan, Damghan and Garmsar, 2002 [In Persian] *J Hormozgan Univ Med Sci.* 2006;1(10):82-77.

62. Sanei-Moghaddam E, Savadkoohi S, Rakhshani F. Prevalence of hepatitis B and C in patients with major Beta-thalassaemia referred to Ali-Asghar hospital In Zahedan, 2002 [In Persian]. *Blood, Sci J Iranian Blood Transfus Org Res Cent.* 2004;1(1):19-26.
63. Akhtar S, Moatter T. Hepatitis C virus infection in polytransfused thalassaemic children in Pakistan. *Indian Pediatr.* 2004;41(10):1072-3.
64. Mohammad J, Hussain M, Khan MA. Frequency of hepatitis B and hepatitis C infection in thalassaemic children. *Pak Pediatr J.* 2003;27:161-64.
65. Younus M, Hassan K, Ikram N, Naseem L, Zaheer HA, Khan MF. Hepatitis C seropositivity in repeatedly transfused thalassaemia major patients. *Int J Pathol.* 2004;2(1):20-3.
66. Burki MF, Hassan M, Hussain H, Nisar Y, Krishan J. Prevalence of anti-hepatitis C antibodies in multiply transfused beta thalassaemia major patients. . *Ann Pak Inst Med Sci.* 2005;1:150-53.
67. Shah MA, Khan MT, Ulla Z, Ashfaq Y. Prevalence of hepatitis B and hepatitis C virus infection in multi-transfused thalassaemia major patients in North West Frontier Province. . *Pak J Med Sci.* 2005;21:281-83.
68. Moatter T, Adil S, Haroon S, Azeemuddin S, Hassan F, Khurshid M. Prevalence of hepatitis G virus in Pakistani children with transfusion dependent beta- thalassaemia major. *Indian J Pathol Microbiol.* 1999;42(4):475-82.
69. Mukhtar Ali Shah, Muhammad Tahir Khan, Zahoor Ulla, Yasmin Ashfaq. Prevalence of Hepatitis B and Hepatitis C virus infection in multi-transfused thalassaemia major patients in North West Frontier Province *Pak J Med Sci.* 2005;21(3):281-3.
70. Hamid Hussain, Rashid Iqbal, Muhammad Hussain Khan, Bushra Iftikhar, Sabina Aziz, Fayaz Khan Burki, et al. Prevalence of Hepatitis C in Beta Thalassaemia Major. *Gomal Journal of Medical Sciences.* 2008; 6(2):87-90.
71. al-Mahroos FT, Ebrahim A. Prevalence of hepatitis B, hepatitis C and human immune deficiency virus markers among patients with hereditary haemolytic anaemias. *Ann Trop Paediatr.* 1995;15(2):121-8.
72. Ramia S, Koussa S, Taher A, Haraki S, Klayme S, Sarkis D, et al. Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics. *Ann Trop Med Parasitol.* 2002;96(2):197-202.
73. Bahakim H, Bakir TM, Arif M, Ramia S. Hepatitis C virus antibodies in high-risk Saudi groups. *Vox Sang.* 1991;60(3):162-4.
74. al-Fawaz I, al-Rasheed S, al-Mugeiren M, al-Salloum A, al-Sohaibani M, Ramia S. Hepatitis E virus infection in patients from Saudi Arabia with sickle cell anaemia and beta-thalassaemia major: possible transmission by blood transfusion. *J Viral Hepat.* 1996;3(4):203-5.
75. Al-Hawsawi Zakaria M. Prevalence of Hepatitis C Virus Antibody. *Annals of Saudi Medicine.* 2000;20(5-6):488-9.
76. el Gohary A, Hassan A, Nooman Z, Lavanchy D, Mayerat C, el Ayat A, et al. High prevalence of hepatitis C virus among urban and rural population groups in Egypt. *Acta Trop.* 1995;59(2):155-61.
77. el-Nanawy AA, el Azzouni OF, Soliman AT, Amer AE, Demian RS, el-Sayed HM. Prevalence of hepatitis-C antibody seropositivity in healthy Egyptian children and four high risk groups. *J Trop Pediatr.* 1995;41(6):341-3. Epub 1995/12/01.
78. Daw MA, Elkaber MA, Draha AM, Werfalli MM, Mihat AA, Siala IM. Prevalence of hepatitis C virus antibodies among different populations of relative and attributable risk. *Saudi Med J.* 2002;23(11):1356-60. Epub 2002/12/31.

Chapter 3

Natural History


Introduction

The majority of HCV-infected patients are asymptomatic, and nowadays the infection is usually detected via screening programs. The natural history of chronic hepatitis C in cohort studies is difficult to define and it can be variable. There are many biases which affect study results such as; those inherent in referral populations, difficulty in establishing the onset of the infection, and limited periods of follow-up (1). Unfortunately no prospective studies exist in which an entire population of infected individuals had been identified at the time of infection and followed systematically over an adequate time period. Based on currently available data different courses of natural history emerge and they depend on; the population studied, duration of the infection in that particular population, how the disease was transmitted, and the relative prevalence of cofactors including gender, age at onset of infection, and alcohol consumption. Older age at HCV exposure,

male gender (2, 3), non-white race (4, 5), higher body mass index (6), and heavy alcohol intake (>40-50 gm/day) (2, 7-11), have been variously identified as factors associated with a more rapid disease progression (12-15). Increased quasi-species diversity in HCV (16, 17), HBV, HIV coinfection (18-22) and cigarette smoking are other factors which affect disease progression.

Although the natural history of chronic HCV infection in patients with thalassemia is unclear, the morbidity and mortality of those patients is thought to be higher. Liver disease is more severe in HCV-infected patients and this may be compounded by hepatic siderosis (23, 24). The prevalence of liver cirrhosis in thalassemia patients with a HCV infection depends on the level of iron chelation in the population studied and it has been reported to be present from 10% to 20% in several studies (25-27) (Figure 3.1).

Figure 3.1. HCV in thalassemia: the importance of iron overload on fibrosis progression



The figure is extracted from the article by Angelucci E et al (26) with permission


Iron overload and HCV infection are independent risk factors for liver fibrosis progression, and their concomitant presence results in a striking increase in risk (26). Male gender, higher alanine aminotransferase (ALT) levels, the existence of an HCV infection, and higher iron concentrations in the liver were significantly associated with severe fibrosis and cirrhosis

(25-28). Hepatitis virus C infection is the main risk factor for liver fibrosis in transfusion-dependent thalassemics. Adequate chelation therapy usually prevents the development of liver fibrosis in thalassemics who are free of a HVC-infection and it also reduces the risk of developing severe fibrosis in thalassemics with chronic hepatitis C.

Iron Overload

Transfusion therapy has greatly improved the survival of transfusion dependent thalassemia major (TM) patients; however, the resultant iron load damages tissues including the heart, liver and endocrine organs. Among these, heart complications still remain the leading cause of mortality in thalassemia major patients who receive transfusion and chelation therapy (29) (Figure 3.2).

Figure 3.2. Why thalassemia patients with HCV infection are very special population?



Close monitoring of individual organ iron concentrations and functioning are thus important for the optimization of individual patient care (30). The ability to determine the amount of iron in the liver and heart by magnetic resonance imaging allows the prescription of the most appropriate chelation regime for these patients and to reassess what the aims, with respect to total body iron, should be. Iron deposits in the liver in thalassemia patients due to chronic hemolytic anemia leads to; tissue damage, collagen formation, portal fibrosis, and progression to liver cirrhosis (31, 32). Hepatocellular carcinoma (HCC) formation is often observed following the formation of severe fibrosis and liver cirrhosis (33). In prospective studies the existence of a HCV infection was the main risk factor for acquiring HCC in thalassemia HCV-infected patients (34, 35).

Recent evidence from Europe has shown that by normalizing iron stores not only are new morbidities prevented, but also reversal of many complications such as; cardiac failure, hypothyroidism, hypogonadism, impaired glucose tolerance, and type 2 diabetes can occur, and it also improves survival rates and patients' quality of life. All these advances in management require the absolute cooperation and understanding of parents, children, and ultimately, the patients themselves. Only with such cooperation can normal long-term survival be achieved, as adherence to treatment is now likely to be the primary barrier to longevity. Unfortunately despite improvements in the life expectancy of thalassemia patients through the use of transfusion and chelation therapy, most of the children born with thalassemia major in developing countries do not have access to sufficient chelation therapies and they often die due to complications of iron overload (29).

HIV and HCV Coinfection

Because HIV and HCV are transmitted in similar ways, it is expected that they will develop together. HIV and HCV infections are basic issues that health systems are faced with in many societies. However, the prevalence of HIV among HCV-infected patients varies according to the distribution of HCV risk factors, with the highest rates being seen in intravenous drug users (36). It is estimated that between 34–38.6 million people around the world are infected with HIV,

compared with 170–200 million by HCV, and 4–5 million people who are coinfecting with HIV and HCV (37). Coinfection of HIV/HCV has a different natural history in comparison with mono-infected cases. HIV increases the progression of the HCV infection, it also increases HCV viral loads and the rate of progression to cirrhosis and hepatocellular carcinoma (38–40). Thalassemia patients have been found to be at higher risk of acquiring HIV-HCV infections and this problem was more prevalent in developing countries (41). Prevalence rates in countries with safer blood transfusion are close to zero and most of the infected patients resulted prior to screening (42, 43).

Hepatocellular Carcinoma

It has been recognized that the most important risk factor for HCC is cirrhosis (44) and iron overload is also a known risk factor for this condition. It seems that the numbers of thalassemia patients who develop HCC will increase in the future and it will be one of the leading clinical problems in thalassemia. It is therefore, reasonable to recommend HCC screening of all thalassemia patients with one or more risk factor since this would facilitate early treatment, leading to improved outcomes (33). Preliminary data suggests an incidence of HCC in thalassemia of about 2%. However, since thalassemia is endemic in many underdeveloped countries where patients are probably not screened for HCC, it is possible that the present knowledge of this issue represents only the tip of the iceberg. Iron chelation appears to play a protective role in the occurrence of HCC (45). There is currently a debate regarding the best treatment for HCC in thalassemia, and liver transplantation is considered a contraindication. Periodic liver ultrasound HCC screening should be considered for thalassemia patients with risk factors for HCC. Prevention of HCV infections through blood transfusion is nowadays, the only known evidence-based means to prevent HCC in thalassemia.

Concluding Remarks

- Iron depletion with iron chelators can stabilize or improve liver fibrosis and histological necroinflammation.
- Male gender, higher ALT levels, existence of a HCV infection, and higher iron concentrations in the liver are significantly associated with severe fibrosis and cirrhosis.
- HIV increases the progression of the HCV infection, increases HCV viral loads and the rate of progression to cirrhosis and hepatocellular carcinoma.
- Thalassemia patients with a HCV infection and liver cirrhosis should be put on surveillance for HCC with periodic liver ultrasounds every six months and alpha-fetoprotein level detection.

References

1. Nguyen HA, Ho SB. Natural history of chronic hepatitis C: identifying a window of opportunity for intervention. *J Lab Clin Med.* 2001;137(3):146-54.
2. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. *Lancet.* 1997;349(9055):825-32.
3. Friedman SL. Evaluation of fibrosis and hepatitis C. *Am J Med.* 1999;107(6B):27S-30S. Epub 2000/02/01.
4. Seeff LB. Natural history of hepatitis C. *Hepatology.* 1997;26(3 Suppl 1):21S-8S.
5. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. *Hepatology.* 1997;26(3 Suppl 1):34S-8S. Epub 1997/09/26.
6. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. *Hepatology.* 1999;29(4):1215-9.
7. Pol S, Fontaine H, Carnot F, Zylberberg H, Berthelot P, Brechot C, et al. Predictive factors for development of cirrhosis in parenterally acquired chronic hepatitis C: a comparison between immunocompetent and immunocompromised patients. *J Hepatol.* 1998;29(1):12-9.
8. Pessione F, Degos F, Marcellin P, Duchatelle V, Njapoum C, Martinot-Peignoux M, et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. *Hepatology.* 1998;27(6):1717-22. Epub 1998/06/10.
9. Schiff ER. The alcoholic patient with hepatitis C virus infection. *Am J Med.* 1999;107(6B):95S-9S. Epub 2000/02/01.
10. Wiley TE, McCarthy M, Breidi L, Layden TJ. Impact of alcohol on the histological and clinical progression of hepatitis C infection. *Hepatology.* 1998;28(3):805-9. Epub 1998/09/10.

11. Corrao G, Arico S. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. *Hepatology*. 1998;27(4):914-9.
12. Freeman AJ, Dore GJ, Law MG, Thorpe M, Von Overbeck J, Lloyd AR, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. *Hepatology*. 2001;34(4 Pt 1):809-16. Epub 2001/10/05.
13. Bird SM, Goldberg DJ, Hutchinson SJ. Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 2: Preliminary UK estimates of prevalent injection-related hepatitis C carriers, and derivation of progression rates to liver cirrhosis by gender and age at hepatitis C virus infection. *J Epidemiol Biostat*. 2001;6(3):267-77; discussion 79-85.
14. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: a meta-analysis. *Clin Gastroenterol Hepatol*. 2005;3(11):1150-9. Epub 2005/11/08.
15. Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. *Hepatology*. 2005;42(3):711-23.
16. Davis GL. Hepatitis C virus genotypes and quasispecies. *Am J Med*. 1999;107(6B):21S-6S.
17. Honda M, Kaneko S, Sakai A, Unoura M, Murakami S, Kobayashi K. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. *Hepatology*. 1994;20(5):1144-51. Epub 1994/11/01.
18. Cropley I, Main J. Hepatitis C virus infection: co-infection with HIV and HBV. *Baillieres Best Pract Res Clin Gastroenterol*. 2000;14(2):265-75.
19. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfecting patients. The Multivirc Group. *Hepatology*. 1999;30(4):1054-8. Epub 1999/09/25.
20. Lesens O, Deschenes M, Steben M, Belanger G, Tsoukas CM. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. *J Infect Dis*. 1999;179(5):1254-8. Epub 1999/04/07.
21. Soto B, Sanchez-Quijano A, Rodrigo L, del Olmo JA, Garcia-Bengochea M, Hernandez-Quero J, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. *J Hepatol*. 1997;26(1):1-5.
22. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. *Lancet*. 1997;350(9089):1425-31.
23. Alavian SM, Tabatabaei SV. Treatment outcome of chronic hepatitis C in sickle cell disease and thalassemic patients with interferon and ribavirin. *Eur J Gastroenterol Hepatol*. 2010;22(1):123-4. Epub 2009/12/05.
24. Zokaei A, Mirmomen SS, Ebrahimi-Daryani N, Haghpanah B, Poorsamimi P, Alavian SM, et al. A comparative study between pegylated versus conventional interferon for the treatment of chronic hepatitis C infection in adult transfusion dependent thalassemic patients: an open label, randomized trial. *Gut*. 2004;36(1):A 169.
25. Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F, et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. *Haematologica*. 2008;93(8):1243-6.
26. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis

- in thalassemia following bone marrow transplantation. *Blood*. 2002;100(1):17-21.
27. Prati D, Zanella A, Farma E, De Mattei C, Bosoni P, Zappa M, et al. A multicenter prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous beta-thalassemia. *Blood*. 1998;92(9):3460-4.
 28. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta-thalassemia major in North America. *Blood*. 2004;104(1):34-9. Epub 2004/02/28.
 29. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Survival and complications in thalassemia. *Ann NY Acad Sci*. 2005;1054:40-7.
 30. Chu WC, Au WY, Lam WW. MRI of cardiac iron overload. *J Magn Reson Imaging*. 2012;36(5):1052-9. Epub 2012/10/24.
 31. Mirmomen S, Alavian SM. Treatment of HCV Infection in Multitransfused Thalassaemic Patients: Does Liver Iron Status Affect the Outcome of Response? *Hepat Mon*. 2005;5(1):11-113.
 32. De Virgiliis S, Cossu P, Sanna G, Frau F, Loi E, Lobrano R, et al. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis. *Acta Haematol*. 1982;67(1):49-56.
 33. Mancuso A. Hepatocellular carcinoma in thalassemia: A critical review. *World J Hepatol*. 2010;2(5):171-4. Epub 2010/12/17.
 34. Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. *Hemoglobin*. 2006;30(1):19-24. Epub 2006/03/17.
 35. Borgna-Pignatti C, Vergine G, Lombardo T, Cappellini MD, Cianciulli P, Maggio A, et al. Hepatocellular carcinoma in the thalassaemia syndromes. *Br J Haematol*. 2004;124(1):114-7. Epub 2003/12/17.
 36. Rezaianzadeh A, Hasanzadeh J, Alipour A, Davarpanah MA, Rajaeifard A, Tabatabaee SH. Impact of Hepatitis C on Survival of HIV-Infected Individuals in Shiraz; South of Iran. *Hepat Mon*. 2012;12(2):106-11. Epub 2012/04/18.
 37. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. *N Engl J Med*. 2007;356(14):1445-54. Epub 2007/04/06.
 38. Klein MB, Lalonde RG, Suissa S. The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. *J Acquir Immune Defic Syndr*. 2003;33(3):365-72.
 39. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. *Jama*. 2002;288(2):199-206.
 40. Sullivan PS, Hanson DL, Teshale EH, Wotring LL, Brooks JT. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy. *Aids*. 2006;20(8):1171-9.
 41. Prakash A, Aggarwal R. Thalassemia Major in Adults: Short Stature, Hyperpigmentation, Inadequate Chelation, and Transfusion-Transmitted Infections are Key Features. *N Am J Med Sci*. 2012;4(3):141-4. Epub 2012/03/29.
 42. Kalantari H, Mirzabaghi A, Akbari M, Shahshahan Z. Prevalence of hepatitis C virus, hepatitis B virus, human immunodeficiency virus and related risk factors among hemophilia and thalassemia patients In Iran. *Iran J Clin Infect Dis*. 2011;6(2):82-4.
 43. Mahmoodzadeh M, Ganji F, Taheri S. Prevalence of HIV Infection in thalassaemic patients receiving blood transfusion in Chaharmahal-Bakhtiari province in 2006. *Iran J Pathol*. 2007;2(2):67-70.
 44. Somi M, H. Hepatocellular Carcinoma. *Hepat Mon*. 2005;5(3):65-76.
 45. Fragatou S, Tsurveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit. *Hemoglobin*. 2010;34(3):221-6. Epub 2010/06/09.

Diagnosis and evaluation

Serological assays

The first step in the diagnosis of HCV infection is the enzyme-linked immunosorbent assay (ELISA) for anti-HCV antibody, detecting past exposure or ongoing infection. Three generations of the ELISA have been developed; the ELISA-3 has a more than 99% sensitivity and specificity. The window for serologic conversion after initial exposure varies within a range of 20–150 days, with a mean of approximately 50 days. False-positive tests are most often seen in low-risk populations, such as blood donors. False-negative tests are most often seen in immunocompromised patients, as is the case of HIV positive subjects or on chemotherapy, also including dialysis patients and transplant recipients. For differentiation between past exposures from ongoing infection, evaluation of HCV RNA by polymerase chain reaction (PCR) is necessary (1-4). In ELISA-3 analyses, a recombinant NS5 antigen has been added to the four antigens used in the second-generation assays. These third-generation assays have a higher sensitivity and speci-

ficity than second-generation assays and suffer a less important influence from the infecting genotype.

The PCR

The second main step in the diagnosis of chronic HCV infection is the detection of HCV RNA in serum. Virus is generally detectable 7–21 days following exposure. There are three main assays available. Detection of HCV RNA by using amplification techniques such as PCR or transcription-mediated amplification (TMA) confirms the presence of ongoing infection with active HCV replication. The sensitivity of PCR for HCV RNA detection may vary according to the choice of primers and the handling of pre-extraction samples. Two different methods have been commonly used for the quantitation of HCV RNA and have become commercially available. The first was developed by Roche Diagnostics Systems (Branchburg, NJ, USA) and is based on a competitive PCR assay for HCV RNA quantitation (Roche Monitor assay). Quantitative HCV RNA by PCR is less sensitive, but still able to detect as few as 100 copies/mL and is able to provide an absolute viral titer. It is currently reported as both copies/mL and as international units/mL (IU/mL).

The second method is based on the co-amplification of synthetically mutated target RNA (branched DNA [bDNA] assay [Quantiplex, Chiron Corp., Emeryville, CA, US]). The quantitative results of HCV RNA detected by both methods are reliable and reproducible. The bDNA technique is the least sensitive. After a World Health Organization (WHO) consensus meeting, a standardized international unit (IU) was established. The WHO concluded that 800,000 IU/mL was the clinically relevant threshold, whereas greater than 800,000 IU/mL was considered a high viral titer while less than 800,000 IU/mL was considered a low viral titer. The distinction is clinically relevant in regard to the likelihood of treatment response.

Genotyping

Hepatitis C virus is a single-stranded RNA virus, and is classified into at least six genotypes, each comprising of multiple subtypes, which have been distributed worldwide (5, 6). The HCV subtypes 1a and 1b are the most common genotypes in the US and these subtypes also are predominant in

Europe. The HCV genotype 3a is particularly prevalent in intravenous drug abusers in Europe and the US. The HCV genotype 4 appears to be prevalent in North Africa and the Middle East, and genotypes 5 and 6 seem to be confined to South Africa and Hong Kong, respectively (7-10).

Although the genotype of infecting virus is one of the primary predictors of response to antiviral therapy, its distribution in polytransfused thalassemic patients is still unclear throughout the world (7). In a study on thalassemia patients in Tehran-Iran, HCV genotype 1a was the most frequent (52%), followed by genotype 3a (34.5%) and genotype 1b (5 %) (11). Samimi-Rad K et al. had also determined that Iranian hemophilic patients have the same HCV genotype distribution as thalassemic patients (12). Our experience in thalassemia patients from the national data base (11) showed that HCV genotype distribution was the following: genotype 1 in 57%, 3 in 35%, 2 in 1%, and mixed in 4%. Genotype 1 was associated with a higher splenectomy rate and a greater serum ferritin. Genotype 1 is the most frequently detected HCV genotype in Iranian patients with thalassemia (11). Table 1 summarizes the HCV genotype distribution among thalassemic patients in different countries. It seems that in Lebanon, genotype 4 is predominant while in Greece, genotypes 1 and 3

Table 4.4. Distribution of HCV genotypes among thalassemic patients in different countries

Author	Country of sample origin	HCV Genotypes					
		Geno-type 1 (%)	Geno-type 2 (%)	Geno-type 3 (%)	Geno-type 4 (%)	Geno-type 6 (%)	Mixed genotype (%)
Chakravarti, A (16)	India	20		36			36
Alavian SM (11)	Iran	57	1	35			4
Khaja MN (17)	India	61		36			
Ramia S (15)	Lebanon	36	5	21	37		
Wong DA (13)	Hong Kong	50				50	
Christofidou M (22)	Greece	32	10	28	30		
Sharara AI (23)	Lebanon	33	4	15	48		

have the same frequency. In Hong Kong, genotype 6 prevails in a noticeable fraction of patients (13-17). In reviews of reported prevalences of HCV genotypes from different parts of the world, it seems that genotypes 1a and 1b are more common (14, 18-21). The determination of HCV genotypes is very useful in the prediction of response to anti-viral therapies and decision making with respect to the duration of therapy.

Liver tests

The elevation of aminotransferase is not required for diagnosis. Up to 30% of patients with chronic HCV have persistently normal alanine aminotransferase (ALT). Patients with normal ALT are significantly younger and weigh less compared with those with elevated ALT, but there is no correlation to gender, race, baseline viral titer or HCV genotype (24). The degree of serum ALT elevation does not correlate well with histological severity.

Liver Histology

Liver biopsy has been the cornerstone and gold standard for the evaluation of liver damage in HCV infected patients and the management of liver diseases (25). Evaluation of the liver specimen by pathologists can show us the current status of liver injury, grade the necrotic inflammatory damage and stage the degree of liver fibrosis while also diagnosing cirrhosis and the presence of steatosis (26-28). The most important assessments in liver biopsy are the determination of grade and stage of liver injury. Another main issue in liver biopsy in thalassemia is the measurement of liver iron concentration (LIC) by atomic absorption spectrometry (29). Hepatitis C virus infection is the main risk factor for liver fibrosis in thalassemia. Adequate chelation therapy usually prevents the development of liver fibrosis in thalassemics free of HCV infection and reduces the risk of developing severe fibrosis in thalassemics with chronic hepatitis C (30).

Non-invasive tests

Liver biopsy is an invasive procedure and it is associated with pain, bleeding and perforation of other organs in some situations (31, 32). In recent

years, transient elastography (TE) was introduced as an ultrasonography technique which uses low frequency elastic waves for estimation of liver tissue, by evaluating the velocity of the propagation of the waves in the liver, in order to assess the severity of liver fibrosis (33, 34). The accuracy of the liver stiffness score is excellent for the diagnosis of cirrhosis; it is probably the most accurate noninvasive method for the early detection of cirrhosis. It is a user-friendly technique that can be performed without any preparation in less than 5 minutes in clinic or at the bedside, with immediate results and high patient acceptance. It is very likely that in future it will become the most widely used technique for the assessment of liver fibrosis (33, 35). This method is relatively new and there is few published data available regarding it in the literature. Recently, some evidence demonstrated that transient elastography can diagnose the existence of liver cirrhosis in thalassemia patients (36, 37).

Iron overload measurements

Patients with thalassemia major receive at least 0.4 mg/kg/day of heme iron, nearly 50 times the physiologic rate of iron absorption (29). Without aggressive iron chelation therapy, these patients die from endocrine and cardiac complications in their second decade of life (38). Chelation therapy is life-saving, but requires close monitoring of iron balance (39). Trends in serum ferritin are useful in tracking chelators responsiveness, are relatively inexpensive and are widely available (40). Ferritin values, however, can be confounded by inflammatory state and may give wildly inaccurate estimates of total body iron in selected patients (41). Liver biopsy can estimate the iron overload, but in patients with severe fibrosis or cirrhosis, there is a variability in iron distribution in the liver (42). Non-invasive methods for measuring liver iron overload such as magnetic resonance imaging (MRI) have been evaluated in thalassemia patients and fortunately there is a good relationship between the quantitation of liver iron concentration by biopsy and MRI signal amplitude using R2 or R2* mapping (43, 44). Heart complication still remains the leading cause of mortality. Myocardial iron deposition can occur independently of other solid organ involvement; conversely, the heart may be spared despite heavy siderosis in other tissues (45).

Conclusion remarks

- Screening of thalassemia patients for HCV infection by using anti-HCV antibody is sensitive and specific.
- For confirming the active replication of HCV, we recommend to evaluate the quantitative serum HCV RNA.
- The HCV genotyping before the start of therapy is strongly recommended.
- Measurement of liver iron concentration using liver biopsy or MRI-R2 is recommended.
- A non-invasive method such as transient elastography is preferable to liver biopsy for excluding existence of liver cirrhosis.

References

1. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. *J Hepatol.* 2000;32(1 Suppl):98-112. Epub 2000/03/23.
2. Chevaliez S, Pawlotsky JM. Hepatitis C virus: virology, diagnosis and management of antiviral therapy. *World J Gastroenterol.* 2007;13(17):2461-6. Epub 2007/06/07.
3. Ferreira MR, Lonardoni MV, Bertolini DA. Hepatitis C: serological and molecular diagnosis and genotype in haemophilic patients at the Regional Hemocenter of Maringa, Maringa PR Brazil. *Haemophilia.* 2008;14:810-5.
4. Skidmore S. Hepatitis C virus—epidemiology and serological diagnosis. *J Med Microbiol.* 1993;39(5):321-2.
5. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology.* 2005;42(4):962-73.
6. Zein NN, Persing DH. Hepatitis C genotypes: current trends and future implications. *Mayo Clin Proc.* 1996;71(5):458-62.s
7. Ahmadi Pour MH, Alavian SM, Amini S, Azadmanesh K. Hepatitis C Virus Genotypes. *Hepat Mon.* 2005;5(3):77-82.
8. Ahmadi Pour MH, Keivani H, Sabahi F, Alavian SM. Determination of HCV genotypes, in Iran by PCR-RFLP. *Iran J Public Health.* 2006;35(4):54-61.
9. Keyvani H, Alizadeh AHM, Alavian SM, Ranjbar M, Hatami S. Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. *Hepatol Res.* 2007;37(2):101-3. Epub 2007/02/16.
10. Amini S, Farahani Majd Abadi M, Alavian SM, Joulaie M, Ahmadipour MH. Distribution of Hepatitis C Virus Genotypes in Iran: A Population-Based Study. *Hepat Mon.* 2009;9(2):95-102.
11. Alavian SM, Miri SM, Keshvari M, Elizee PK, Behnava B, Tabatabaei SV, et al. Distribution of hepatitis C virus genotype in Iranian multiply transfused patients with thal-

- assemia. *Transfusion*. 2009;49:2195-9. Epub 2009/06/23.
12. Samimi-Rad K, Shahbaz B. Hepatitis C virus genotypes among patients with thalassaemia and inherited bleeding disorders in Markazi province, Iran. *Haemophilia*. 2007;13(2):156-63.
 13. Wong DA, Tong LK, Lim W. High prevalence of hepatitis C virus genotype 6 among certain risk groups in Hong Kong. *Eur J Epidemiol*. 1998;14(5):421-6.
 14. Christofidou M, Lambropoulou-Karatza C, Dimitracopoulos G, Spiliopoulou I. Distribution of hepatitis C virus genotypes in viremic patients with beta-thalassaemia. *Eur J Clin Microbiol Infect Dis*. 2000;19(9):728-30.
 15. Ramia S, Koussa S, Taher A, Haraki S, Klayme S, Sarkis D, et al. Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics. *Ann Trop Med Parasitol*. 2002;96(2):197-202.
 16. Chakravarti A, Verma V. Distribution of hepatitis C virus genotypes in beta-thalassaemic patients from Northern India. *Transfus Med*. 2006;16(6):433-8. Epub 2006/12/14.
 17. Khaja MN, Madhavi C, Thippavazzula R, Nafeesa F, Habib AM, Habibullah CM, et al. High prevalence of hepatitis C virus infection and genotype distribution among general population, blood donors and risk groups. *Infect Genet Evol*. 2006;6(3):198-204.
 18. Di Marco V, Bronte F, Sicily Grp Study T. HCV clearance among hemophiliacs and beta-thalassaemics. *Gastroenterology*. 2007;132(4):1634-.
 19. Chakravarti A, Verma V, Kumaria R, Dubey AP. Anti-HCV seropositivity among multiple transfused patients with beta thalassaemia. *J Indian Med Assoc*. 2005;103(2):64-6.
 20. Li CK, Chik KW, Lam CW, To KF, Yu SC, Lee V, et al. Liver disease in transfusion dependent thalassaemia major. *Arch Dis Child*. 2002;86(5):344-7. Epub 2002/04/24.
 21. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, et al. Hepatic iron overload does not prevent a sustained virological response to interferon-alpha therapy: a long term follow-up study in hepatitis C-infected patients with beta thalassaemia major. *Am J Gastroenterol*. 2002;97(4):982-7.
 22. Christofidou M, Jelastopulu E, Economides G, Spiliopoulou I, Siagris D, Labropoulou-Karatza C, et al. Epidemiology of chronic hepatitis C virus infection in high risk groups. *Hepat Mon*. 2008;8(1):11-6.
 23. Sharara AI, Ramia S, Ramlawi F, Fares JE, Klayme S, Naman R. Genotypes of hepatitis C virus (HCV) among positive Lebanese patients: comparison of data with that from other Middle Eastern countries. *Epidemiol Infect*. 2007;135(3):427-32. Epub 2006/07/20.
 24. Persico M, Perrotta S, Persico E, Terracciano L, Folgore A, Ruggeri L, et al. Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years. *J Viral Hepat*. 2006;13(5):290-6.
 25. McCaughan GW, Omata M, Amarpurkar D, Bowden S, Chow WC, Chutaputti A, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. *J Gastroenterol Hepatol*. 2007;22(5):615-33. Epub 2007/04/21.
 26. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. *J Hepatol*. 1995;22(6):696-9. Epub 1995/06/01.
 27. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. *Hepatology*. 1996;24(2):289-93. Epub 1996/08/01.
 28. Adibi P, Alavian SM, Mohammadalizadeh A, Zali MR, Sima H. Could a clinician decide about HCV treatment without liver biopsy: estimating clinical decision prediction and statistical agreement? *Gut*. 2004;36(1):A300.

29. Prati D, Maggioni M, Milani S, Cerino M, Cianciulli P, Coggi G, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. *Haematologica*. 2004;89(10):1179-86. Epub 2004/10/13.
30. Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F, et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. *Haematologica*. 2008;93(8):1243-6.
31. Alavian SM, Mirmomen S. Liver biopsy is not necessary but helpful sometimes. *Hepat Mon*. 2004;4(7):85-6.
32. Nassiri-Toosi M, Ghanati H, Azmoudeh Ardalan F, Agdarkosh H, Safai SR, Lak M, et al. Assessment of safety and Efficacy of Transjugular liver biopsy as a diagnostic method in adult patients with congenital bleeding disorders with HCV infection. *Iran J Radiol*. 2004;1(1-2):73-8.
33. Malekzadeh R, Poustchi H. Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy. *Hepat Mon*. 2011;11(3):157-8. Epub 2011/11/17.
34. Aalaei-Andabili SH, Mehrnoush L, Salimi S, Shafiei M, Alavian SM. Liver Hemangioma Might Lead to overestimation of Liver Fibrosis by Fibroscan; A Missed Issue in Two Cases. *Hepat Mon*. 2012;12(6):408-10. Epub 2012/08/11.
35. Parsian H, Alizadeh M, Negahdar H. Would the physicians eventually obsolete the liver biopsy for the assessment of liver fibrosis? *Hepat Mon*. 2012;12(5):353-4. Epub 2012/07/12.
36. Di Marco V, Bronte F, Cabibi D, Calvaruso V, Alaimo G, Borsellino Z, et al. Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE)-lack of interference by iron deposition. *Br J Haematol*. 2010;148(3):476-9. Epub 2009/11/26.
37. Fraquelli M, Cassinerio E, Roghi A, Rigamonti C, Casazza G, Colombo M, et al. Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. *Am J Hematol*. 2010;85(8):564-8. Epub 2010/07/27.
38. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. *J Pediatr*. 1991;118(4 Pt 1):540-5. Epub 1991/04/01.
39. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Survival and complications in thalassemia. *Ann NY Acad Sci*. 2005;1054:40-7.
40. Bonkovsky HL, Slaker DP, Bills EB, Wolf DC. Usefulness and limitations of laboratory and hepatic imaging studies in iron-storage disease. *Gastroenterology*. 1990;99(4):1079-91. Epub 1990/10/01.
41. de Virgiliis S, Sanna G, Cornacchia G, Argioli F, Murgia V, Porcu M, et al. Serum ferritin, liver iron stores, and liver histology in children with thalassaemia. *Arch Dis Child*. 1980;55(1):43-5. Epub 1980/01/01.
42. Emond MJ, Bronner MP, Carlson TH, Lin M, Labbe RF, Kowdley KV. Quantitative study of the variability of hepatic iron concentrations. *Clin Chem*. 1999;45(3):340-6. Epub 1999/03/03.
43. Wood JC. Magnetic resonance imaging measurement of iron overload. *Curr Opin Hematol*. 2007;14(3):183-90. Epub 2007/04/07.
44. Wood JC. Diagnosis and management of transfusion iron overload: the role of imaging. *Am J Hematol*. 2007;82(12 Suppl):1132-5. Epub 2007/10/30.
45. Chu WC, Au WY, Lam WW. MRI of cardiac iron overload. *J Magn Reson Imaging*. 2012;36(5):1052-9. Epub 2012/10/24.

Chapter 5

Treatment

Introduction

Acute hepatitis C has become relatively rare in recent years, and this is mainly due to a reduction in post-transfusion cases. However, HCV alone is responsible for 90% of acute hepatitis in poly-transfused patients and 60% to 80% of these cases develop chronic hepatitis, consequently these patients are at risk of acquiring cirrhosis and hepatocellular carcinoma (1, 2). In those patients who become acutely infected, the disease is often mild or completely asymptomatic, and it is rarely recognized outside prospective surveillance, after exposure to known risk factors, or in a surveillance system for the periodic checking of HCV infections in high risk groups, such as thalassemia patients (3). Several studies have reported on the efficacy of interferon therapy for acute HCV infections in adults. Using interferon α -2b monotherapy for 24 weeks, Jaeckel et al. showed a 98% sustained virological response in a cohort of 44 patients with an acute HCV infection (4).

The use of the newer pegylated interferons (PEG-IFN) in the treatment of adults with acute HCV has subsequently been described as producing equally excellent results (5). A single case report showed the successful treatment of acute hepatitis C with weight-based dosing of peginterferon α -2b in an eight year-old child with thalassemia major, after high viral loads had persisted for 12 weeks following the diagnosis of an acute icteric HCV infection (6).

The primary goal of therapy for chronic HCV infections is viral eradication. The efficacy of antiviral treatment of HCV is measured through the sustained virological response (SVR), which is operationally defined as the absence of HCV RNA for at least 24 weeks after the end of treatment (7, 8). Reaching SVR not only prevents advancement towards cirrhosis, HCC and liver failure, but it may also improve patients' quality of life (9, 10). Prolonged antiviral treatment with numerous complications and medical costs on the one hand and the multiplicity of factors affecting response to treatment on the other, warrant the identification of predictive variables for reaching SVR as a leading morbidity prevention factor in selected populations (11). The treatment regimen for chronic hepatitis C has changed significantly over the past decades in the antiviral treatment of HCV infections and combination therapy of peginterferon-ribavirin has become the standard around the world (1, 12).


Definitions of Treatment Response

During combination treatment of chronic hepatitis C virus infection with anti-viral drugs, analysis of HCV RNA levels at specific time points has become a useful instrument for assessing treatment efficacy. The kinetics of HCV RNA during therapy is one of the most useful variables in predicting response or non-response to therapy.


A virological response in chronic HCV is defined as a reduction of HCV RNA levels in the serum (at least 2 logs) and ideally by the absence of any detectable HCV RNA by a qualitative reverse transcriptase-polymerase chain reaction (PCR) assay with a sensitivity of approximately 100 copies (50 IU) per ml. Testing should be performed early during treatment (particularly at the decision-making point at 12 weeks), at the end of treatment and six months later (13). HCV RNA quantitation at treatment

week 12 is used as a time-point to decide whether to continue or to stop treatment in genotype 1 infections (14-16). Patients with a negative HCV RNA test at week 12 of the therapy period have a high probability of achieving SVR; on the other hand, no patients with a positive serum HCV RNA after 12 weeks achieved SVR (7, 17, 18). On the evidence of many clinical trials and published guidelines (12, 19-22) the most effective duration of therapy in genotype 1 and 4 is 48 weeks and in genotype 2 or 3 it is 24 weeks (Figure 5.1) (Figure 5.2).

Figure 5.1. Response guided therapy in patients with genotype 1



If an early viral response has not been reached after 12 weeks of therapy, meaning a lack of HCV RNA level decline of >2 log from baseline or a negative qualitative test (<50 IU/ml), treatment is generally stopped. These patients have only a small likelihood of achieving SVR after 48 weeks of treatment. Recently, a negative HCV RNA treatment response in week four, rapid viral response (RVR), has been used to decide whether a shorter-than-standard treatment course can be used or not, particularly in those patients with genotype 1 infections who have low baseline viral loads ($<600\ 000$ IU/ml) (23). This also seems to be valid for patients infected with genotype 2 or 3, for the latter in those with a low baseline viral load ($<600\ 000$ IU/ml), for whom a rapid viral response indicates that a shorter-than-standard

Figure 5.2. Response guided therapy in patients with genotype 2/3

treatment (12–16 weeks) can be used with reasonably preserved SVR (24–28). Sustained viral response rates are defined by the absence of detectable HCV RNA in the serum by a sensitive (qualitative) PCR assay six months after completion of treatment. Relapse can occur following an end-of-treatment response, which is indicated by a recurrence of detectable HCV RNA (and often ALT elevation) after discontinuing therapy. Non-response can be defined as the continued presence of HCV RNA at the end of treatment, the reappearance of HCV RNA after end virological response (EVR) (break-through), or failure to achieve a 2-log reduction of viral load at 12 weeks. In a virological sense, it includes partial and absolute non-response, but the implications of these fine distinctions for prognosis and retreatment, are not yet clear (13).

Slow virological responders who had positive HCV RNA at 12 weeks of therapy, but were negative at 24 weeks of therapy, and received the 72-week therapy, had a significantly higher probability of achieving SVR than their counterparts who received only the 48-week therapy [RR = 1.44 (95% CI, 1.20–1.73)]. This meta-analysis showed that the 72-week therapy with peginterferon and ribavirin is significantly superior to the standard 48-week therapy in slow responders with a HCV genotype 1 infection (29) (Figure 5.1).

The COBAS Amplicor Monitor with a lower detection limit of <600 IU/ml was earlier used frequently as a HCV RNA quantitative test, however, this has recently been substituted with the COBAS TaqMan test with a lower detection limit of <15 IU/ml (30).

Counseling

There have been conflicting reports about the sexual transmission of HCV infections. The detection of anti-HCV positivity ranged from 0% to 5% in monogamous partners of transfusion-associated hepatitis patients (31-33). A possible explanation is that sexual transmission occurs only in association with specific HCV genotypes or in the presence of specific mutations along the HCV genome. The risk of HCV transmission in non-sexual household members of thalassemia patients is possible, but it is very low (34, 35). We should not forget that there are some reports in household contacts of thalassemia patients with HCV, high prevalence of HCV infections for example from Pakistan and India (36, 37). It is clear that the high prevalence is related to higher contact with other risk factors in their communities, or it may be related to sharing shaving equipment which is a common source of infection (38).

Management of HCV infections in thalassemia patients needs a multidisciplinary team involving a hematologist, hepatologist, cardiologist, psychologist, and endocrinologist. Consultation with a psychiatrist for evaluation of the existence of depression and management of it before therapy and an eye consultation for a retina examination before the start of anti-viral drug therapy are necessary. Thalassemia patients have cardiomyopathy and they should be carefully evaluated before the start of therapy and sometimes after therapy as well. Patients with severe, uncontrolled cardiomyopathy should be excluded from anti-viral therapy.

General measures

According to our data, strict iron chelation to decrease serum and liver iron content before and during ribavirin therapy of thalassemia patients is strongly advised. The decision on the treatment and monitoring of thalassemia major patients should be carefully individualized according to any

other conditions that accompany patients' underlying hemoglobinopathy. Moreover, by close observation and frequent transfusion, the rate of severe hemoglobin drop can be minimized, as maintaining hemoglobin levels above 8-9 g/dl is necessary. High iron content in the serum and liver with its probable role in conferring patients' interferon resistance and its synergistic effect on the progression of liver fibrosis is another major confounder in the treatment of thalassemia major patients. Increased hepatic iron deposition has been shown to correlate with the severity of hepatic inflammation and fibrosis in patients with chronic hepatitis C, and impair responses to IFN-based therapy (39, 40). Some studies have suggested that iron depletion is an adjuvant to antiviral therapy in chronic HCV infections and showed that iron removal and dietary iron restriction could improve the rate of response to IFN (41, 42). Proper management of hepatic siderosis before the initiation of HCV therapy in thalassemia patients is therefore essential. Thalassemia major patients have high iron stores and the proper removal of iron with chelating drugs is not always successful, or it may not be properly implemented in all situations (43). Concerning chelation treatment, while deferiprone may increase the risk of neutropenia, no findings on the safety of deferasirox in association with combined antiviral treatment have so far been reported in the literature. Therefore, switching to deferoxamine treatment during antiviral treatment for hepatitis C can be recommended (44).

Antiviral therapy

Treatment of HCV in thalassemia patients aims to eradicate the virus, facilitate improvements in liver damage, avoid fibrosis progression, decrease the risk of hepatocellular carcinoma, improve health-related quality of life and patients' survival (43). Unfortunately, there is a deficit of data regarding the management of this special group and most clinical trials exclude this group from studies (45). Chronic hepatitis C (CHC) is a major cause of morbidity and mortality in thalassemia major patients, particularly in those who had received their first transfusion before the introduction of the HCV donor screening program. Interferon alpha is the backbone of treatment for chronic HCV, it is a glycoprotein that has direct antiviral mechanisms and it also has processes for the enhancement of immune responses to the virus.

IFN Monotherapy

Monotherapy with interferon at three million units, three times a week for 48 weeks produces low sustained virological response rates of less than 20% (46-50). In reported studies using alpha interferon monotherapy with three million units, three times per week, for a duration of 24-48 weeks (regime used in most studies) in thalassemia the response rate differs from 20% to 50%, which depends on the genotype and other variables (51-60). The presence of cirrhosis, high iron concentrations in the liver tissue and genotype 1b are the main clinical and virological characteristics which predict a poor response to therapy (7, 17, 18).

Pegylated interferons have a covalently attached polyethylene glycol moiety that results in more sustained absorption and reduced clearance. This has allowed a once weekly dose, compared with the three times weekly dose required for standard interferon. The safety profile is similar to standard interferon. There is little data regarding the use of pegylated interferon alone in thalassemia patients infected with HCV infection in the literature.

The first report was done by Mirmomen et al. in Iran as a multicenter study using Pegasys 180 microgram once per week for one year. In total, 32 subjects, 18 to 42 years-of-age received the therapy and the SVR was 60.8% (61). This very high response rate was remarkable in the thalassemia patients and therefore the question is. Why was the SVR rate in Iranian thalassemia patients higher than expected? After six years we found that Iranian HCV infected patients had a favorable IL-28 B polymorphism that increased the SVR in the study population (61-64).

Inati et al. (65) administered 180 microgram of Pegasys weekly, for 12 months, in 12 thalassemia HCV-infected patients, and 33% (4 out of 12) achieved SVR. The patients tolerated the drug very well and being younger than 18 years was an important variable in the prediction of SVR (65). Kamal et al. (66) reported a 46% SVR by using Pegasys 180 microgram weekly, for 12 months, in 39 thalassemia HCV infected patients in 2006. Kountouras et al. (67) reported a SVR of 13% by using pegylated alpha interferon 2b (PegIntron), 1.5 microgram/kilogram/week, for 48 weeks in thalassemia HCV infected patients (67). The study group had a 24% dropout rate and in 19% of patients the rate of transfusion was increased.

Combination with Ribavirin

The treatment of chronic HCV infection has improved significantly over the past several years with combination PEG IFN and ribavirin therapy. SVR is achievable in nearly half of the patients with genotype 1 and about 80% of those with genotypes 2 and 3 (14, 68, 69). In view of the high cost and the significant side effects of this combination therapy, it is important to identify patients who are most likely to benefit from it before starting treatment (70). SVR in the real world is different from clinical trials reports and we should judge each case separately. Although combination therapy of pegylated interferon and ribavirin significantly increases SVR and increases the probability of reaching SVR by 50% (71), the degree of response depends on a variety of factors and these may differ in diverse patient populations (71). Viral genotype, viral load, patient age, BMI, race, environment and several other factors have been shown to correlate with SVR (7, 72, 73).

In patients without hemoglobinopathies, current guidelines strongly recommend a combination therapy of ribavirin, and either peginterferon alfa-2a or 2b. This combination therapy can yield a SVR rate of more than 50% in genotype 1 and a 70-80% SVR in genotype 2 and 3 infected patients (6-10). In contrast, in patients without inherent hemoglobinopathy, ribavirin which is one of the major determinants of SVR can induce life-threatening anemia in thalassemia major patients, and thus, it is generally considered contraindicated in these patients (11, 12). Currently, IFN without ribavirin is widely approved as a first-line therapy for chronic HCV infection in transfusion-dependent thalassemia patients. The introduction of combination therapy with interferon alpha, injected subcutaneously three times per week, and daily oral ribavirin is a major advance (74), but the main problem with thalassemia is the exacerbation of anemia after the use of ribavirin. We thus have a double edged sword, if we use interferon as a monotherapy we will have a low response rate, and if we use ribavirin we will have more requests for blood transfusions.

As mentioned above, the main limitations in the treatment of HCV infections in thalassemia patients relate to ribavirin use. Consensus statements have listed anemia as an absolute contraindication to ribavirin in hepatitis C, because of the tendency of ribavirin and its metabolites to accumulate within the erythrocytes, leading to oxidative damage of red blood cell mem-

branes and hemolysis (75). Because of potential hematologic adverse events ribavirin is, however, reserved for IFN non-responders or for use in experimental situations (45). In fact, ribavirin can increase SVR in thalassemia patients with a HCV infection and it can be well tolerated, but due to the induction of hemolysis the need for blood transfusions increases 30-60%, and it also leads to an increase in iron overload. More recently, trials comparing peginterferon monotherapy and the combination of peginterferon and ribavirin have shown a considerable increase in SVR rates in the dual therapy arm, albeit at the cost of a modest increase in transfusion requirements. In fact, SVR rates in these relatively small trials were comparable to treatment in experienced patients without thalassemia or hepatic iron overload (43, 65, 76-83).

In the largest study in the world, conducted in Iran on 280 thalassemia patients (76), Tabatabaei et al. compared the monotherapy group (pegylated interferon alpha 2-a 180 microgram/weekly) with a combination group (pegylated interferon alpha 2-a 180 micrograms plus ribavirin). Baseline characteristics of the studied patients are in (table 5.1). As presented in Table 1 most of the major predictors of virological response including HCV RNA level, sex, weight, BMI, HCV type, age and liver histological findings, appeared to be similar in both groups.

Table 5.1. Baseline Characteristics of Studied Patients

Patients Characteristics	Group (A)	Group (B)	P
No. of patients	199	81	
Sex			
Male/Female M (%)	123/76 (62%)	42/39 (60%)	0.1
Mean Age	24±5.5	25±7.2	0.3
range	11-43	12-54	
BMI	20.4±0.2	20.2±0.2	
range	14-28	15-25	
ALT (U/L)	91±56	79±60	0.06
Range	12-994	15-338	0.02
Normal (<40 U/L), n (%)	35 (18%)	24 (30%)	
Elevated, n (%)	164 (82%)	57 (70%)	
AST (U/L)	77±61	64±41	0.08
Range	17-638	13-206	
Normal (<40 U/L), n (%)	43 (22%)	29 (36%)	0.01
Elevated, n (%)	156 (78%)	62 (64%)	

Hb	10±1.5	9.5±1.3	0.4
HCV viral load (IU/mL)	800000±11000	799000±88000	
range	2000-8000000	7540-4090000	
Log10 Serum HCV Viral Load (IU/mL)	5.5±0.7	5.5±0.6	0.5
>6 (copy/ml), n (%)	85 (43%)	31 (38%)	
Serum ferritin (ng/mL)	2130±1777	1710±1498	0.06
range	210-8132	300-6650	
History of Splenectomy			
Yes/No Y (%)	135/64 (68%)	49/32 (60%)	0.2
HCV Type			
Genotype 1, n (%)	119 (60%)	41 (51%)	0.1
Genotype 2, n (%)	1 (0.5%)	2 (2.5%)	
Genotype 3, n (%)	65 (33%)	33 (41%)	
Mixed infection, n (%)	10 (5%)	2 (2.5%)	
Untypable, n (%)	4 (2%)	3 (4%)	
Stage of liver fibrosis	3.2±1.6	3.3±1.4	0.5
0-2, n (%)	50 (31%)	16 (20%)	0.3
3-4, n (%)	69 (43%)	37 (53%)	
5-6, n (%)	41 (26%)	17 (24%)	
Grade of liver inflammation	6.3±0.2	6.3±0.4	0.9
0-6, n (%)	92 (59%)	43 (63%)	0.7
7-12, n (%)	58 (37%)	23 (34%)	
13-18, n (%)	7 (4.5%)	2 (3%)	
Stage of Liver Sidrosis	3±1	2.9±1	
0-2	37 (19%)	16 (20%)	0.2
3-4	118 (59%)	34 (42%)	
Previous treatment	136 (68%)	38 (47%)	0.001
Naïve	61 (31%)	43 (53%)	0.0006
Standard IFN	62 (31%)	24 (30%)	0.8
Standard IFN+RVB	74 (37%)	14 (17%)	0.001

*Plus-minus values indicate means ±SD. except for liver enzymes and serum ferritin there were no significant differences among the two treatment groups with regard to baseline characteristics. ALT denotes alanine aminotransferase, AST aspartat aminotransferase, Hb hemoglobin and HCV hepatitis C virus.

*Hepatitis C virus level was determined with the use of the amplicor assay version II (Roche), for which the lower limit of quantitation is 50 IU per milliliter.

*Percutaneous liver-biopsy specimens obtained before treatment were evaluated according to modified knodell score scaling system. The modified knodell scoring system classifies fibrosis according to a 6-point scale: 0, no fibrosis; 1, Fibrous expansion of some portal areas; 2, Fibrous expansion of most portal areas; 3, Fibrous expansion of most portal areas with occasional portal to portal bridging; 4, Fibrous expansion of portal areas with marked bridging of portal to portal as well as portal to central; 5, Marked bridging with occasional nodules; 6, Cirrhosis.

Ref: Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. *Hepat Mon.* 2012;12(6):372-81 with permission

Our primary efficacy analysis showed that the SVR rate was significantly higher in group (A) patients who received the combination therapy with low dose ribavirin in comparison with patients of group (B) who received monotherapy. Furthermore, multiple logistic-regression analysis with adjustment for baseline characteristics revealed that low dose ribavirin was an even stronger independent predictor of a SVR than had been shown in our primary analysis. Sustained virological response (SVR) was significantly higher in patients who received ribavirin (51% vs. 38% $P = 0.02$). In a multivariate regression, an OR of ribavirin for the prediction of SVR was 2.2 (95% CI 1.24-3.91). The SVR was significantly higher in the ribavirin group in subgroups of patients older than 24 years-of-age, elevated ALT, ferritin < 2006 ng/mL, previous treatment failure, genotype 1, positive history of splenectomy, fibrosis score of 0-4 HAI and viral load < 600 000 IU/mL. Treatment discontinuation due to safety concerns were comparable between the treatment groups (6.5% and 8%). Furthermore, transfusion intervals were almost halved in patients who received low dose ribavirin. These findings are consistent with the results of previous studies (7, 84, 85). Although in non-thalassemia patients, higher liver and serum iron content have been shown to undermine the virological response to anti-HCV therapy, no study except for one case report, has reported this phenomenon among thalassemia patients (45, 84-88). Serum ferritin and a liver pearl score did not reach significance level for predicting SVR among the total studied population in the present investigation. Nonetheless, our subgroup analysis showed that patients with serum ferritin levels below 2006 ng/mL responded to ribavirin significantly more positively than those with a lower level of serum ferritin. Relapse rates were 23% for combination therapy and 35% for monotherapy ($P=0.01$). In a multivariate binary logistic regression we found that; being female, age below 24 years, and non-1 genotype, were independently associated with SVR, conversely; age over 24, genotype-1 and not receiving ribavirin, were significant predictors of relapse.

Other factors related to treatment such as; the necessity of peginterferon dose reduction, discontinuation of treatment, and compliance with therapy, were similar in both treatment arms. More patients discontinued their treatments owing to an insufficient therapeutic response in group (A), rather than group (B). The higher rate of previous treatment failure in

group (A), even with ribavirin, could be a possible reason for this finding. The safety profile was similar among these two groups; treatment discontinuations due to adverse events were observed in 6.5% to 8.6% of patients, respectively. However, the transfusion interval was almost halved in the patients who had received ribavirin (Table 5.2).

This large prospective study showed that low dose ribavirin in chronically HCV infected thalassemia patients is safe, tolerable and effective. Accord-

Table 5.2. Adverse Events in The Study Patients

Adverse events	Group (A)		Group (B)	
	N	Percent	N	Percent
Death	3	1.5%	5	6%
Non-response	21	10%	5	6%
Dose Reduction	39	19%	15	18%
Neutropenia	33	16%	11	13%
Thrombocytopenia	6	3%	4	5%
Headache	46	23%	20	25%
Lethargy	41	21%	11	12%
Dizziness	23	12%	8	10%
Insomnia	34	17%	12	15%
Irritability	67	34%	23	28%
Depression	15	7%	10	12%
Fatigue	60	30%	19	23%
Weight loss	12	6%	3	3.7%
Flue like syndrome	11	5%	5	6%
Myalgia	65	33%	26	32%
Arthralgia	59	30%	23	28%
Nausea	11	5%	4	5%
Diarrhea	13	6%	4	5%
Cough	19	9%	9	11%
Alopecia	85	43%	33	41%
Dry skin	26	13%	21	26%
Pruritis	19	9%	3	4%
Rash	5	2%	3	4%
Chills	23	12%	13	16%
Fever	48	24%	23	28%

Ref: Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. *Hepat Mon.* 2012;12(6):372-81 with permission

ing to the present study, adult thalassemia patients with HCV infections can be treated successfully with low dose ribavirin. Hence, we strongly advise combination therapy in thalassemia patients with the aforementioned clinical characteristics. On the other hand, ribavirin does not seem to be beneficial in thalassemia patients below 18 years-of-age (76).

The major impact of low dose ribavirin was found in thalassemia major patients who were; older than 24 years, had low serum ferritin (<2006 ng/mL), previous treatment failure, elevated ALT, liver fibrosis of 0-4 HAI, history of splenectomy, viral load \leq 600 000 IU/mL, and HCV genotype 1.

In a meta-analysis of the literature concerning the treatment of chronic hepatitis C in polytransfused thalassemic patients, we have demonstrated that thalassemic patients with a genotype 1 infection benefited significantly from the addition of ribavirin to their therapeutic regimen (8). Table 1 shows the summery of the literature on the treatment of HCV in thalassemia is presented in Table 2.

This meta-analysis (Table 5.3 - 5.4) showed that thalassemia patients with a genotype 1 infection improved notably with the addition of ribavirin to their therapeutic regimen with a doubling of SVR rates, from 30% to 61%, similar to non-thalassemia patients (45) (Tables 5.5 - 5.6). It seems that the addition of ribavirin to IFN increases the SVR rate in genotype 1-infected subjects more than in non-genotype 1-infected thalassemic individuals. Rate of SVR. Using ribavirin in thalassemia patients increases transfusion needs by a median of 30–40%, but it does not increase major adverse events or treatment withdrawal (8, 76) (Figures 5.3 - 5.4). Based on the above evidence, I would like to emphasize the benefits achieved through the addition of ribavirin to peginterferon in thalassemia patients with a HCV infection. This combination is relatively safe and effective and should be considered particularly in the expert management of hematologic disorders setting (Table 5.7).

Despite improvements in treatments for HCV infection, not all patients are cured with anti-viral therapy. Patients, who have contraindications to antiviral therapy or have failed previous cycles of antiviral therapy, should be monitored regularly. This monitoring is even more important in patients with severe fibrosis of the liver or who are cirrhotic. This needs to in-

Table 5.3. Summary of the literature data: studies and patients' characteristics

Study Characteristics				Patients Characteristics								
Author	Study design	Sample Size	Publication year	Country of sample's origin	Sex (% m)	Age y	Genotype 1 and 4	Serum ferritin ($\mu\text{g/l}$)	Liver iron content $\mu\text{g/gm}$	HCV viral load Copy/ml	Stage of fibrosis	ALT IU/ml
1 Di Marco, (16) 42	Prosp	12	1992	Italy	46%	13	ND	2490	ND	ND	ND	294
2 Donohue, (21) 144	Prosp	12	1993	UK	60%	20	ND	2917	ND	ND	2.2	221
3 Clemente, M. G. (24) 33	CT	51 T 14 C	1994	Italy	ND	14	ND	2195	19* $\mu\text{g/gm}$	ND	ND	261
4 Telfer, P. T. (32) 133	Prosp	11	1997	UK	ND	27	45%	2967	10 $\mu\text{g/mg}$	22 \times 10 ⁶	ND	116
5 Di Marco (33) 134	Prosp	70	1997	Italy	47%	14	58%	3241	72 $\mu\text{g/g}$	ND	ND	111
6 Spiliopoulou, I. (27) 105	Prosp	13	1999	Greece	38%	14	69%	ND	ND	0.2 \times 10 ⁶	2.6	129
7 Pizzarelli, G (15) 206	CT	38 T 13 T 28 C	1999	Italy	57% 53%	14 17	100% 100%	3946 4234	12* 12* $\mu\text{g/dL}$	ND	ND	195 186
8 Sievert, W. (26) 101	Prosp	28	2002	Australia	60%	26	42%	1026	2808 $\mu\text{g/g}$	1.6 \times 10 ⁶	1.5	105
9 Li, C. K. (31) 132	Prosp	18	2002	China	50%	16	77%	2142	5.4 mg/g	ND	ND	ND
10 Mirmomen (36) 75	Prosp	29	2003	Iran	ND	25	ND	ND	ND	ND	ND	ND
11 Mirmomen (25) 74	Prosp	32	2004	Iran	59%	24	46%	1712	ND	ND	3.7	92
12 Artan, R. (28) 123	Prosp	10	2005	Turkey	50%	17	ND	2959	ND	ND	ND	93
13 Inati, A. (29) 124	RCT	12 T 8 T	2005	Lebanon	73% 75%	22 16	100%	1763 2757	8 mg/g 8.2	0.3 \times 10 ⁶ 0.4 \times 10 ⁶	ND	86 103
14 Syriopoulou, V. (30) 126	Prosp	89	2005	Italy	52%	20	14%	3192	ND	ND	2.9	190
15 Kountouras, D (35) 197	Prosp	37	2007	Spain	43%	34	65%	2295	ND	ND	ND	106
16 Harmatz, P (34) 185	Prosp	21	2008	USA	ND	33	57%	1541	5.8	ND	2	74

Ref: Alavian SM, Tabatabaeei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat. 2010;17(4):236-44 with permission

Table 5.4. Summary of the literature data: characteristics of treatment and response

Author	Treatment characteristics						Sustained viral response	End of treatment response	Dropout rate
	protocol	IFN doses	RBV doses (mg/day)	Duration w	Interferon total dose				
1 Clemente, M. G. (24) 33	IFN α 2b	3		60	540	37%	41%	0%	
2 Di Marco, * (16) 42	IFN α 2b	5+3		8+18	282	ND	ND	47%	
3 Sievert, W. (26) 101	IFN α 2b	3		24	216	28%	28%	7%	
4 Spiliopoulou, I. (27) 105	IFN α 2b	3		72	648	76%	100%	15%	
5 Artan, R (28) 123	IFN α 2a	5		24-48	720	80%	ND	0%	
6 Syriopoulou, V. (30) 126	IFN α 2a	3		48	432	52%	55%	4%	
7 Di Marco (33) 134	IFN α 2b	5+3		8+40	480	40%	40%	4%	
8 Donohue, * (21) 144	IFN α 2b	3		24	216	ND	ND	0%	
9 Pizzarelli, *G (15) 206	IFN α 2a	5+3		24+24	576	ND	ND	47%	
	IFN α 2b	3		48	432				
10 Mirmomen (36) 75	IFN α 2b	3		48	432	31%	52%	7%	
11 Mirmomen (25) 74	PEG α 2b	180		48	8640	43%	81%	6%	
12 Kountouras, D (35) 197	PEG α 2b	1.5 μ g/kg/wk		48	4320*	13%	27%	24%	
13 Inati, A. (29) 124	PEG α 2b+RVB	180	6-10 mg/kg	48	8640	62%	75%	0%	
	PEG α 2b+PLC					33%	41%		
14 Li, C. K. (31) 132	IFN α 2b+RVB	3	16 mg/kg	48	432	72%	72%	0%	
15 Telfer, P. T. (32) 133	IFN α 2b+RVB	3	1000	24	216	45%	63%	0%	
16 Harmatz, P (34) 185	PEG α 2a+RVB	180	800-1200*	24-48	8640	33%	ND	23%	

*excluded from meta-analysis because SVR was not reported

Ref: Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat. 2010;17(4):236-44 with permission

Table 5.5. rate of sustain viral response in genotype 1 infected thalassemic subjects reported in six trials

Author	Mode of therapy	Responders	Non-responders
		Genotype 1, % (n/N)	Genotype 1, % (n/N)
Sievert, W. (26) 101	Mono	37.5 (3/8)	47.3 (9/19)
Syriopoulou, V. (30) 126	Mono	37.5 (6/16)	36.8 (7/19)
Di Marco (33) 134	Mono	39 (11/28)	71.4 (30/42)
Li, C. K. (31) 132	Combination	76.9 (10/13)	80 (4/5)
Telfer, P. T. (32) 133	Combination	50 (2/4)	42.8 (3/7)
Harmatz, P (34) 185	Combination	75 (6/8)	50 (6/12)

Ref: Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat. 2010;17(4):236-44 with permission


Table 5.6. Rates of sustained viral response in subgroups of patients stratified according therapeutic agents and genotypes

Subgroup of patients	No. of patients	Rate of sustained viral response (95% CI)	Heterogeneity assessment		
			Q (df)	I ²	P value
Genotype 1 (overall)	97	42.2% (26.6-57.8)	10.672 (5)	53.1%	0.058
Genotype 1 who received standard IFN monotherapy	66	29.5% (18.7-40.4)	1.724 (2)	0%	0.422
Genotype 1 who received combination therapy of standard IFN plus ribavirin	31	60.9% (32.4-89.4)	1.533 (1)	53.3%	0.216
Non-genotype 1 (overall)	84	48.6% (38.3-59)	5.702 (5)	12.3%	0.336
Non-genotype 1 who received standard IFN monotherapy	66	51.9% (39.9-63.9)	0.888 (2)	0%	0.642
Non-genotype 1 who received combination therapy of standard IFN plus ribavirin	18	51.5% (23.3-79.6)	2.107 (1)	52.5%	0.147
PEG-IFN monotherapy	77	28.4% (17.2-52.8)	8.838 (2)	77.3%	0.012
PEG-IFN plus ribavirin combination therapy	33	43.6% (29.4-57.8)	2.80 (2)	28.5%	0.247
Standard IFN monotherapy	277	46.9% (35.1-58.7)	25.027 (6)	76%	<0.0001
Standard IFN plus ribavirin combination therapy	29	63% (46.1-80)	2.163 (1)	53.7%	0.141
Ribavirin combination therapy	62	52.9% (33.7-72.2)	7.71 (3)	74%	0.052

P<0.100 considered significant for heterogeneity assessment; df, degree of freedom calculated by number of trials minus 1


Ref: Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. J Viral Hepat. 2010;17(4):236-44 with permission

Figure 5.3. Pooled odd ratio of SVR rate in genotype 1 vs non-genotype 1 infected thalassemic patients with IFN monotherapy



Ref: Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. *J Viral Hepat.* 2010;17(4):236-44 with permission

Figure 5.4. Pooled odd ratio of SVR rate in genotype 1 vs non-genotype 1 infected thalassemic patients with ribavirin combination therapy



Ref: Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. *J Viral Hepat.* 2010;17(4):236-44 with permission

Table 5.7. side effects and cause of withdrawal reported by authors

Author	Side effects	Dropout cause
1 Clemente, M. G. (24)	Granulocytopenia (n=6) fever, fatigue, anorexia and thrombocytopenia were frequent	
2 Di Marco, (16)	ND	persisting fever (n=1) Hyperhemolysis (n=2)
3 Sievert, W. (26)	ND	Death (n=1) ND (n=1)
4 Spiliopoulou, I. (27)	Fever (n=4), weight loss (n=5), anorexia (n=2) headache, myalgia, arthralgia, neutropenia and thrombocytopenia (n=0)	Weight loss (n=1)
5 Artan, R (28)	ND	
6 Syriopoulou, V. (30)	ND	Death (n=4)
7 Di Marco (33)	Mild flu-like syndrome (n=70) Hyperhemolysis (n=1)	persistent flu-like symptoms (n=2)
8 Donohue, (21)	Mild neutropenia (n=7) severe Neutropenia (n=3)	
9 Pizzarelli, G (15)	Cutaneous reaction to DFX (n=5) Coomb's positive hemolytic Anemia (n=1), neutropenia (n=2), thrombocytopenia (n=4)	
10 Mirmomen (36)	Flu syndrome (n=29), chills or fever (n=14), local pain (n=14), transient gastrointestinal symptoms in (n=13), weakness (n=5), local induration (n= 3) and edema (n=2)	illegal concurrent medication usage (n=1) hypothyroidism (n=1)

11	Mirmomen (25)	Weight loss (n=10), alopecia (n=5), flue like syndrome (n=31), fever (n=9), leucopenia (n=5), anorexia (n=10), local injection pain (n=10), thrombocytopenia (n=4)	Death (n=1)
12	Kountouras, D (35)	increased Transfusion requirements (n=7) others ND	increased transfusion rate (n=9) arrhythmia (n=1), EBV pericarditis (n=1), allergy (n=1), leucopenia (n=2), thrombocytopenia (n=1)
13	Inati, A. (29)	increased Transfusion requirements (n=12), leucopenia (n=1)	
14	Li, C. K. (31)	fever, chills, anorexia and malaise were common 30% increased in the annual blood consumption during treatment	
15	Telfer, P. T. (32)	Mild neutropenia (n=3) 41% increased in transfusion during treatment	
16	Harmatz, P (34)	Neutropenia (n=11), Flu-like symptoms (n=11), Headache (n=11), fatigue (n=10), nausea (n=9), Weight loss (n=2), Irritability (n=4), Abdominal pain (n=6), Insomnia (n=7), Alopecia (n=2), Anxiety (n=2),	Death (n=1) persistent cough (n=1) extreme fatigue (n=1) pregnant spouse (n=1)

Ref: Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. *J Viral Hepat.* 2010;17(4):236-44 with permission

clude; biochemical parameters, ultrasound analysis of the liver structure, and transient elastography (Fibroscan), if available, every 6-12 months to follow the evolution from chronic hepatitis to cirrhosis and to monitor patients with cirrhosis for HCC (44).

Management of Side Effects

Numerous side effects have been reported to occur with anti-viral therapy. The major types of side effects include; influenza-like symptoms such as fever and chills, gastrointestinal disturbances, psychiatric symptoms such as depression, insomnia, lack of concentration, hematologic abnormalities (leucopenia, neutropenia, and thrombocytopenia), thyroid dysfunction, and occasionally respiratory and dermatologic symptoms such as hair loss, dry skin, and skin rashes (89). These side effects may be treatment limiting and require dose reduction or drug discontinuation (90-92). Pegylated interferons have significantly improved pharmacokinetics, resulting in improved antiviral efficacy, and they also have the potential to alter the side effect profile (93, 94). Most side effects are mild and reversible and are amenable to control, however, some of them are severe and can even be life threatening. Premature withdrawal from therapy due to laboratory abnormalities or adverse events has occurred in at least 15% of patients and dose reduction in 20-30% combination therapy patients (14, 90, 92, 94, 95). Injection site reactions and injection site inflammation are particularly common, but they are generally mild and rarely dose limiting (68). Numerous case reports of serious adverse events, although infrequent, may occur with therapy and cause significant morbidity and end-organ damage. A partial list includes; acute psychosis, suicidal ideation or attempt, confusion and coma, personality changes, memory loss, retinopathy, retinal hemorrhage, visual loss, neuropathy, tinnitus, hearing loss, photosensitivity, severe skin rash, cardiac arrhythmias, congestive heart failure, interstitial pneumonitis, acute renal failure, bacterial infections (particularly in patients with cirrhosis and thalassemia), and induction or exacerbation of autoimmune diseases (type 1 diabetes mellitus, celiac disease, thrombocytopenic purpura, myasthenia gravis, and lupus-like syndrome) (96-106).

Neutrophil counts decrease within the first two weeks of therapy initiation and usually stabilize over the next four weeks (14, 68, 94). Neutrophil

counts rapidly return to baseline after therapy is discontinued. Dose reduction of peginterferon alpha-2b is recommended when neutrophil counts are lower than 759 cells/mm, this appears to be based on empiric evidence extrapolated from patients undergoing cancer chemotherapy, and the administration of granulocyte colony stimulating factor should be advised. Decreases in platelet counts occur with therapy, but they have been associated infrequently with dose reduction or discontinuation.

The tendency to exacerbate diabetes mellitus, infection and septicemia, should be considered in patients on anti-viral therapy and they should be diagnosed early for better control and to reach SVR. Significant ocular complications such as an irreversible decrease in visual acuity may develop in patients treated with pegylated interferon. The most important risk factor for developing retinopathy is hypertension. The high rate of retinopathy in patients with hypertension and diabetes mellitus suggests that patients should be carefully monitored (107).

Adherence to therapy appears to influence sustained viral response rates. Adherence is a complex human behavior, therefore, the issue of adherence should be attended to in any protocol as the management of side effects can increase patients' adherence rates. This indicates the need for more research on the management of side effects related to both interferon and ribavirin. Improving compliance with therapy through measures such as; patient education, close follow-up, adequate treatment of side effects, and minimization of dose changes may increase the efficacy of treatment (90).

IL28B Polymorphism

Different sustained virological response (SVR) rates in various populations is a challenging fact that has been observed by researchers and inspired them to search for causes (64). In September 2009, Ge et al. (108) in a genome-wide association study (GWAS) found the rs12979860 single nucleotide polymorphism (SNP), which is located three kb upstream of the IL28B gene, to be the strongest host genetic predictor of SVR in hepatitis C genotype 1. They observed that rs12979860 CC patients, regardless of their ethnicity, reach SVR rates approximately twice as often as rs12979860 TT patients. Our experience showed that Iranian, and especially the thalas-

semia patients, responded better to anti-viral therapy in comparison with the literature (62, 63, 109).

Concluding Remarks

- We should give assurances to thalassemia patients with HCV infections and their household contacts regarding the low risk of transmission in the family. However, they should consider health precautions regarding not sharing personal equipment in the family.
- Adult thalassemia patients with a HCV infection can be treated successfully with low dose ribavirin. Hence, we strongly advise combination therapy in thalassemia patients with the aforementioned clinical characteristics.
- However, ribavirin does not seem to be beneficial in thalassemia patients below 18 years. Please treat them early!
- When using ribavirin in thalassemia patients, transfusion needs increase by a median of 30–40%, thus it is important to maintain hemoglobin levels above 8–9 g/dl
- Using suitable iron chelators for the control of iron over load is recommended.
- The duration of therapy in genotype 1 and 4 is 48 weeks and for genotype 2 and 3 it is 24 weeks. In slow responders an extension of further therapy over the following 24 weeks in all of the above groups is recommended.
- Checking IL28 B polymorphism before the start of therapy, to ensure better prediction of responsiveness to anti-viral therapy, is recommended.
- In patients with liver cirrhosis or failure to therapy, periodic monitoring is recommended.

References

1. Alavian SM. Optimal Therapy for Hepatitis C. *Hepat Mon.* 2004;4(2):41-2.
2. Blum HE. Hepatocellular carcinoma: HCC. *Hepat Mon.* 2011;11(2):69-70. Epub 2011/11/17.
3. Bagheri Lankarani K. Acute Hepatitis C Infection. *Hepat Mon.* 2004;4(7):43-7.
4. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med.* 2001;345(20):1452-7.
5. Kamal SM, Fouly AE, Kamel RR, Hockenjós B, Al Tawil A, Khalifa KE, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. *Gastroenterology.* 2006;130(3):632-8.
6. Sharara AI, Aoun E, Koussa S, Inati A, Taher A. Treatment of acute hepatitis C in a child with thalassemia major using weight-based peginterferon alpha-2b. *J Gastroenterol Hepatol.* 2006;21(7):1221. Epub 2006/07/11.
7. Alavian SM, Tabatabaei SV, Keshvari M, Behnava B, Miri SM, Elizee PK, et al. Peginterferon alpha-2a and ribavirin treatment of patients with haemophilia and hepatitis C virus infection: a single-centre study of 367 cases. *Liver Int.* 2010;30(8):1173-80. Epub 2010/07/16.
8. Alavian SM, Behnava B, Tabatabaei SV. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. *Hepat Mon.* 2010;10(2):121-31. Epub 2010/04/01.
9. Asadi Noghahi AA, Zandi M, Mehran A, Alavian SM, Dehkordi AH. The effect of education on quality of life in patients under interferon therapy. *Hepat Mon.* 2010;10(3):218-22. Epub 2010/07/01.
10. Asadi Noughahi AA, Zandi M, Mehran A, Alavian SM, Hasanpour Dehkordi A. The assessment of education's effect on quality of life in patients under PDferon treatment. *J Iran Univ Med Sci.* 2007;14(56):21-8.
11. Mihm U, Herrmann E, Sarrazin C, Zeuzem S. Review article: predicting response in hepatitis C virus therapy. *Aliment Pharmacol Ther.* 2006;23(8):1043-54. Epub 2006/04/14.
12. Alavian SM, Mirmomen S, Bagheri-Lankarani K, Adibi P, Merat SH. Management of hepatitis C infection (regional guideline). *Hepat Mon.* 2004;4:2-19.
13. Teoh NC, Farrell GC. Management of chronic hepatitis C virus infection: a new era of disease control. *Intern Med J.* 2004;34(6):324-37. Epub 2004/07/02.
14. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med.* 2002;347(13):975-82.
15. Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. *Hepatology.* 2003;37(3):600-9.
16. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology.* 2003;38(3):645-52.
17. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. *Hepat Mon.* 2012;12(9):e6151. Epub 2012/10/23.
18. Alavi Moghaddam M, Zali MR, Aalaei Andabili SH, Derakhshan F, Miri SM, Alavian SM. High Rate of Virological Response to Peginterferon alpha-2a-Ribavirin Among Non-Cirrhotic Iranian Hemophilia Patients With Chronic Hepatitis C. *Iran Red Crescent Med J.* 2012;14(8):466-9. Epub 2012/10/30.

19. Myers RP, Ramji A, Bilodeau M, Wong S, Feld JJ. An update on the management of hepatitis C: Consensus guidelines from the Canadian Association for the Study of the Liver. *Can J Gastroenterol.* 2012;26(6):359-75. Epub 2012/06/22.
20. Wilde JT, Mutimer D, Dolan G, Millar C, Watson HG, Yee TT, et al. UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011. *Haemophilia.* 2011;17(5):e877-83. Epub 2011/06/11.
21. Kumada H, Okanou T, Onji M, Moriwaki H, Izumi N, Tanaka E, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. *Hepatol Res.* 2010;40(1):8-13. Epub 2010/02/17.
22. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, et al. Management of chronic hepatitis C: consensus guidelines. *Can J Gastroenterol.* 2007;21 Suppl C:25C-34C.
23. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. *J Hepatol.* 2006;44(1):97-103.
24. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. *Hepatology.* 2004;40(6):1260-5. Epub 2004/11/24.
25. Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. *Hepatology.* 2008;47(1):35-42.
26. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. *N Engl J Med.* 2005;352(25):2609-17. Epub 2005/06/24.
27. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. *Gastroenterology.* 2005;129(2):522-7.
28. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. *N Engl J Med.* 2007;357(2):124-34. Epub 2007/07/13.
29. Alavian SM, Tabatabaei SV, Behnava B, Mahboobi N. Optimal duration of treatment for HCV genotype 1 infection in slow responders: a meta-analysis. *Hepat Mon.* 2011;11(8):612-9. Epub 2011/12/06.
30. Carlsson T, Quist A, Weiland O. Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methods. *J Med Virol.* 2008;80(5):803-7.
31. Ideo G, Bellati G, Pedraglio E, Bottelli R, Donzelli T, Putignano G. Intrafamilial transmission of hepatitis C virus. *Lancet.* 1990;335(8685):353. Epub 1990/02/10.
32. Tahan V, Karaca C, Yildirim B, Bozbas A, Ozaras R, Demir K, et al. Sexual transmission of HCV between spouses. *Am J Gastroenterol.* 2005;100(4):821-4. Epub 2005/03/24.
33. Vandelli C, Renzo F, Romano L, Tisminetzky S, De Palma M, Stroffolini T, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. *Am J Gastroenterol.* 2004;99(5):855-9.
34. Vegnente A, Iorio R, Saviano A, Fariello I, Aponte S, Nasca MG, et al. Lack Of Intrafamilial Transmission Of Hepatitis-C Virus In Family Members Of Children With Chronic Hepatitis-C Infection. *Pediatric Infectious Disease Journal.* 1994;13(10):886-9.
35. Papanastasiou DA, Spiliopoulou I, Katinakis S, Karana-Ginopoulou A, Repanti M. Lack of transmission of hepatitis C in household contacts of children with homozygous beta-thalassaemia. *Acta Haematol.* 1997;97(3):168-73.
36. Sood A, Midha V, Sood N, Awasthi G. Prevalence of anti-HCV antibodies among family

- contacts of hepatitis C virus-infected patients. *Indian J Gastroenterol.* 2002;21(5):185-7. Epub 2002/11/06.
37. Akhtar S, Moatter T, Azam SI, Rahbar MH, Adil S. Prevalence and risk factors for intrafamilial transmission of hepatitis C virus in Karachi, Pakistan. *J Viral Hepat.* 2002;9(4):309-14.
 38. Umar M, Bushra HT, Ahmad M, Data A, Khurram M, Usman S, et al. Hepatitis C in pakistan: a review of available data. *Hepat Mon.* 2010;10(3):205-14. Epub 2010/07/01.
 39. Burt MJ, Cooksley WG. The influence of iron on chronic hepatitis C. *J Gastroenterol Hepatol.* 1998;13(3):330-3.
 40. Van Thiel DH, Friedlander L, Fagiuoli S. Response to interferon alpha therapy is influenced by the iron content of the liver. *J Hepatol.* 1994;20(3):410-5.
 41. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. *Am J Gastroenterol.* 2002;97(5):1204-10.
 42. Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, Mattioli M, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. *Eur J Gastroenterol Hepatol.* 1997;9(5):497-503.
 43. Alavian SM, Lankarani KB, Sharara A. Treatment of Chronic HCV in Special Populations: Thalassemia, Hemophilia, and Hemodialysis Patients. *Curr Hepat Rep.* 2012;11(4):256-62.
 44. Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, et al. Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. *Blood.* 2010;116(16):2875-83. Epub 2010/06/17.
 45. Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused thalassaemic patients: a meta-analysis. *J Viral Hepat.* 2010;17(4):236-44. Epub 2009/07/30.
 46. Hoofnagle JH, di Bisceglie AM. The treatment of chronic viral hepatitis. *N Engl J Med.* 1997;336(5):347-56. Epub 1997/01/30.
 47. Poynard T, Leroy V, Mathurin P, Cohard M, Opolon P, Zarski JP. Treatment of chronic hepatitis C by interferon for longer duration than six months. *Dig Dis Sci.* 1996;41(12 Suppl):99S-102S.
 48. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. *Hepatology.* 1996;24(4):778-89.
 49. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. *J Hepatol.* 1995;23(5):487-96.
 50. Carithers RL, Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. *Hepatology.* 1997;26(3 Suppl 1):83S-8S.
 51. Dimarco V, Loiacono O, Almasio P, Diquattro O, Fabiano C, Craxi A. Treatment of chronic hcv infection with alfa-interferon in beta-thalassemia. *Hepatology.* 1994;19(4):159-1.
 52. Dimarco V, Loiacono O, Capra M, Grutta S, Ciaccio C, Gerardi C, et al. Alpha-interferon treatment of chronic hepatitis-c in young-patients with homozygous beta-thalassemia. *Haematologica.* 1992;77(6):502-6.
 53. Di Marco V, Bronte F, Sicily Grp Study T. HCV clearance among hemophiliacs and beta-thalassemics. *Gastroenterology.* 2007;132(4):1634-.
 54. Di Marco V, Lo Iacono O, Almasio P, Ciaccio C, Capra M, Rizzo M, et al. Long-term efficacy of alpha-interferon in beta-thalassemics with chronic hepatitis C. *Blood.*

- 1997;90(6):2207-12. Epub 1997/10/06.
55. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, et al. Effect of iron overload on the response to recombinant interferon- α treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. *J Pediatr*. 1994;125(1):123-8.
 56. Spiliopoulou I, Repanti M, Katinakis S, Karana-Ginopoulou A, Papanastasiou DA. Response to interferon α -2b therapy in mutitransfused children with beta-thalassemia and chronic hepatitis C. *Eur J Clin Microbiol Infect Dis*. 1999;18(10):709-15.
 57. Syriopoulou V, Daikos GL, Kostaridou SL, Manolaki N, Nakopoulou L, Kattamis A, et al. Sustained response to interferon α -2a in thalassaemic patients with chronic hepatitis C. A prospective 8-year follow-up study. *Haematologica*. 2005;90(1):129-31. Epub 2005/01/12.
 58. Pizzarelli G, Di Gregorio F, Romeo MA, Carboni F, Gallisai D, Solinas A, et al. Interferon- α therapy in Sicilian and Sardinian polytransfused thalassaemic patients with chronic hepatitis C. *Biodrugs*. 1999;12(1):55-63.
 59. Artan R, Akcam M, Yilmaz A, Kocacik D. Interferon α monotherapy for chronic hepatitis C viral infection in thalassaemics and hemodialysis patients. *J Chemother*. 2005;17(6):651-5. Epub 2006/01/26.
 60. Donohue SM, Wonke B, Hoffbrand AV, Reittie J, Ganeshaguru K, Scheuer PJ, et al. Alpha interferon in the treatment of chronic hepatitis C infection in thalassaemia major. *Br J Haematol*. 1993;83(3):491-7. Epub 1993/03/01.
 61. Mirmomen S, Ebrahimi DN, Malekzadeh R, Zali MR, Alavian SM, Haghpanah B, et al. The Efficacy and Safety of Peginterferon Alpha-2a (PEGASYS) Monotherapy in the Treatment of Chronic Hepatitis C infected Subjects with Transfusion Dependent Thalassaemia. *Hepat Mon*. 2004;4(7):65-70.
 62. Sharafi H, Alavian SM. IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. *Hepat Mon*. 2011;11(12):958-9. Epub 2012/03/01.
 63. Sharafi H, Pouryasian A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, et al. Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response. *Hepat Mon*. 2012;12(3):190-5. Epub 2012/05/03.
 64. Alavian SM. Are the Real HCV Infection Features in Iranian Patients the Same As What Is Expected? *Hepat Mon*. 2005;5(1):3-5.
 65. Inati A, Taher A, Ghorra S, Koussa S, Taha M, Aoun E, et al. Efficacy and tolerability of peginterferon α -2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. *Br J Haematol*. 2005;130(4):644-6. Epub 2005/08/16.
 66. Kamal S, Fouly A, Mohamed S, et al. Peginterferon α -2b therapy with and without ribavirin in patients with thalassemia: a randomized study. Presented at the 41st Annual Meeting of the European Association for the Study of the Liver, 26-30 April 2006, Austria Center, Vienna, Austria, abstract 585.
 67. Kountouras D, Koskinas J, Berdoussi H, Vgontza N, Karagiorga M, Lagiandreou A, et al. Efficacy and safety of PEG-IFN α -2B treatment for 48 weeks in adult thalassaemic patients with chronic HCV infection. *Journal of hepatology*. 2007;46:S190-S1.
 68. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon α -2b plus ribavirin compared with interferon α -2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*. 2001;358(9286):958-65.
 69. Hadziyannis SJ, Koskinas JS. Differences in epidemiology, liver disease and treatment

- response among HCV genotypes. *Hepato Res.* 2004;29(3):129-35. Epub 2004/06/19.
70. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncalves FL, Jr., et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. *J Hepatol.* 2005;43(3):425-33.
 71. Alavian SM, Lankarani KB, Aalaei-Andabali SH, Pouryasini A, Ebrahimi Daryani N, Nasiri Toosi M, et al. Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader's Meeting-28th July 2011-Tehran, IR Iran. *Hepat Mon.* 2011;11(9):703-13.
 72. Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, et al. Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy. *Antivir Ther.* 2009;14(1):45-54. Epub 2009/03/27.
 73. Rodriguez-Torres M, Jeffers LJ, Sheikh MY, Rossaro L, Ankoma-Sey V, Hamzeh FM, et al. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. *N Engl J Med.* 2009;360(3):257-67. Epub 2009/01/16.
 74. Saracco G, Olivero A, Ciancio A, Carezzi S, Rizzetto M. Therapy of chronic hepatitis C: a critical review. *Curr Drug Targets Infect Disord.* 2003;3(1):25-32. Epub 2003/02/07.
 75. Ancel D, Amiot X, Chaslin-Ferbus D, Hagege I, Garioud A, Girot R, et al. Treatment of chronic hepatitis C in sickle cell disease and thalassaemic patients with interferon and ribavirin. *Eur J Gastroenterol Hepatol.* 2009. Epub 2009/05/01.
 76. Tabatabaei SV, Alavian SM, Keshvari M, Behnava B, Miri SM, Karimi Elizee P, et al. Low dose ribavirin for treatment of hepatitis C virus infected thalassemia major patients; new indications for combination therapy. *Hepat Mon.* 2012;12(6):372-81. Epub 2012/08/11.
 77. Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. *Haematologica-the Hematology Journal.* 2008;93(8):1247-51.
 78. Harmatz P, Olivieri NF, Kwiatkowski J, Vichinsky E, Giardina P, Shah F, et al. Safety and efficacy of peginterferon Alfa-2a and ribavirin for hepatitis C in thalassemia. *Blood.* 2006;108(11):168A-A.
 79. Hamidah A, Thambidorai CR, Jamal R. Peginterferon alfa-2b and ribavirin in thalassaemia/chronic hepatitis C virus-co-infected non-responder to standard interferon-based. *Med J Malaysia.* 2005;60(4):517-9.
 80. Li CK, Chan PK, Ling SC, Ha SY. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in thalassaemia major. *Br J Haematol.* 2002;117(3):755-8. Epub 2002/05/25.
 81. Telfer PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoffbrand AV, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. *Br J Haematol.* 1997;98(4):850-5. Epub 1997/11/05.
 82. Sherker AH, Kermack D. Combination therapy with alpha-2b interferon and ribavirin is safe and effective in the treatment of chronic hepatitis C infection in patients with transfusion-dependent thalassemia major. *Hepatology.* 2001;34(4):595A.
 83. Sherker AH, Senosier M, Kermack D. Treatment of transfusion-dependent thalassaemic patients infected with hepatitis C virus with interferon -2b and ribavirin. *Hepatology.* 2003;37(1):223.
 84. Ladero JM, Lopez-Alonso G, Devesa MJ, Cuenca F, Ortega L, Agreda M, et al. Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C. *Rev Esp Enferm Dig.* 2009;101(1):31-40. Epub 2009/04/02.
 85. Alavian SM, Tabatabaei SV. Therapy of hepatitis C in thalassemia: the influence of

- iron on achieving sustained viral response. *Ann Hematol.* 2010;89(2):215-6. Epub 2009/07/11.
86. Franchini M, Targher G, Capra F, Montagnana M, Lippi G. The effect of iron depletion on chronic hepatitis C virus infection. *Hepatology Int.* 2008;2(3):335-40. Epub 2009/08/12.
 87. Fujita N, Sugimoto R, Urawa N, Araki J, Mifuji R, Yamamoto M, et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. *J Gastroenterol Hepatol.* 2007;22(11):1886-93.
 88. Taher AT, Musallam KM, Khalife M, Barada K. Hepatitis C antiviral response in thalassemia: what is the role of liver iron concentration? *Ann Hematol.* 2009;88(10):1033-4. Epub 2009/03/04.
 89. Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. *Semin Liver Dis.* 1999;19 Suppl 1:67-75.
 90. Lankarani K. How to manage side effects of interferon alpha therapy in Chronic Hepatitis C? *Hepatitis Monthly.* 2004;4(6):5-8.
 91. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. *Semin Liver Dis.* 1999;19 Suppl 1:57-65.
 92. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). *Lancet.* 1998;352(9138):1426-32.
 93. Alavian SM, Mirmomen S, Bagheri-Lankarani K, Adibi P, Merat S. Management of hepatitis C infection (regional guideline) *Hepatitis Monthly.* 2004;4:2-19.
 94. Fried MW. Side effects of therapy of hepatitis C and their management. *Hepatology.* 2002;36(5 Suppl 1):S237-44. Epub 2002/10/31.
 95. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. *N Engl J Med.* 1998;339(21):1485-92.
 96. Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. *Br J Ophthalmol.* 2001;85(10):1171-3.
 97. Hejny C, Sternberg P, Lawson DH, Greiner K, Aaberg TM, Jr. Retinopathy associated with high-dose interferon alfa-2b therapy. *Am J Ophthalmol.* 2001;131(6):782-7. Epub 2001/06/01.
 98. Nadir A, Amin A, Chalisa N, van Thiel DH. Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. *J Viral Hepat.* 2000;7(6):466-70. Epub 2000/12/15.
 99. Cadoni G, Marinelli L, De Santis A, Romito A, Manna R, Ottaviani F. Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis. *J Laryngol Otol.* 1998;112(10):962-3.
 100. Alavian SM, Hajarizadeh B. Attempted suicide in two patients with chronic hepatitis C while being treated with interferin-alpha. *Hepatitis Monthly.* 2004;4:20-2.
 101. Toosi M, Hassanabadi M. Hearing Loss as a Complication of Peginterferon Alfa 2a Combination Therapy in a Patient with Hepatitis C Virus Infection. *HEPATITIS MONTHLY.* 2004;4(7):79-82.
 102. Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. *Am J Med Sci.* 2001;322(4):233-5.

103. Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. *Chest*. 1994;105(3):939-41.
104. Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. *Muscle Nerve*. 2002;25(6):909-13.
105. Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. *Jpn Heart J*. 1996;37(6):905-15.
106. Fujiwara T, Kiura K, Ochi K, Matsubara H, Yamanari H, Shimomura H, et al. Giant negative T waves during interferon therapy in a patient with chronic hepatitis C. *Intern Med*. 2001;40(2):105-9.
107. Kim ET, Kim LH, Lee JI, Chin HS. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. *Jpn J Ophthalmol*. 2009;53(6):598-602. Epub 2009/12/19.
108. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature*. 2009;461(7262):399-401. Epub 2009/08/18.
109. Mahboobi N, Behnava B, Alavian SM. IL28B SNP genotyping among Iranian HCV-infected patients: A preliminary report. *Hepat Mon*. 2011;11(5):386-8. Epub 2011/11/17.



Author message:

Thalassemia patients have high prevalence rates of hepatitis C virus (HCV) infections. Recent improvements in the survival of these patients are a result of more services in the control of iron overload, the provision of safe blood and better control of complications. Today, liver disease is the main cause of mortality in thalassemia patients throughout the world. Unfortunately, there are inadequate policies in most thalassemia centers for the control of HCV infections. I considered it imperative to provide a book from A to Z for health professionals regarding the epidemiology, screening, diagnosis and treatment of HCV infection in this high risk group. My hope is for better control of HCV in thalassemia patients in the world, especially in the Mediterranean region.

Author information:

Alavian is a professor of medicine and hepatologist, he established the first hepatitis clinic in 1995, at the Iranian Blood Transfusion Service in Tehran, and he is one of the founders of the Iranian Charity for Liver Support in Tehran, established in 1995. He has been the associate editor of the Journal of Clinical Virology from 2004. Prof. Alavian works as an advisor and consultant on national program projects for the control of hepatitis in Iran and he is also the founder and Editor-in-chief of Hepatitis monthly journal. He has been a member of the National Committee for Hepatitis in the Iranian Ministry of Health and Medical Education since 1995. Alavian is an experienced researcher and hepatologist who has been actively involved in various national multicenter clinical trials and basic scientific projects related to viral hepatitis over the past 19 years. He has authored/co-authored over 320 articles in both local and international journals. He was the principal investigator in numerous clinical trials related to the management and treatment of hepatitis C and B patients. His main interests are; health policy, epidemiological aspects of viral hepatitis, and methods of integrating new protocols for the control of these infections. He is also interested in clinical trials of emerging medications for hepatitis B virus and hepatitis C virus infections, along with the treatment of viral hepatitis in particular diseases, including thalassemia and hemophilia. He is the founder and director of the Middle East Liver Disease (MELD) Centers which were established in Iran, in 2012, and the program has expanded throughout the entire region with the collaboration of scientists in both Middle East and Middle Asian countries.



Meld Center



The Brilliant Future of Publishing
www.KowsarPub.com

COMING SOON

Kowsar Publishing



